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Numerous epidemiological studies link vascular disorders, such as hypertension,
diabetes and stroke, with Alzheimer’s disease. Hypertension, specifically, is an
important modifiable risk factor for late onset Alzheimer’s disease. Despite the
abundance of clinical data connecting these conditions, animal studies investigating
the connection between the two are lacking.

To examine the link between midlife hypertension and the onset of Alzheimer’s
disease later in life, chronic hypertension was induced in the TgSwDI mouse model
of Alzheimer’s disease in early adulthood using long-term administration of the
eNOS inhibitor, Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME). L-NAME
treatment accelerated cognitive deficits, microvascular deposition of the amyloidbeta peptide, vascular inflammation, blood brain barrier leakage, and pericyte loss in
these mice.

Though lysosomal markers were increased in hypertensive TgSwDI mice relative to
all other groups, autophagic structures appeared to be increased in both
hypertensive TgSwDI mice, as well as hypertensive WT mice. The increased

presence of these structures altered cellular morphology at the neurovascular unit
and compromised the blood brain barrier in hypertensive mice.

Additionally, midlife hypertension induced hippocampal neurodegeneration at an
early age in TgSwDI mice. Neuronal loss is a defining characteristic of pathology in
Alzheimer’s disease, but is not replicated in many mouse models of the disease.
Therefore, this may be a useful research model of Alzheimer’s disease with mixed
vascular and amyloid pathologies and may display classical features of the disease
missing in more canonical mouse models.

To Jason Morris and, of course, to Mom.
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CHAPTER 1: INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia and there is no
universal cause, prevention or treatment to delay or stop its progression. Familial
forms of the disease often involve mutations in genes that result in overproduction of
the amyloid-beta peptide (Aβ)1, although this is not the cause of the disease in all
cases. Such mutations affect the expression of the amyloid precursor protein (APP),
which produces Aβ when cleaved. Mutations affecting production or function of
presenilin-1 or 2 (PS-1 or -2), which function as part of the gamma-secretase
intramembrane protease complex, can also result in production of the cleaved
peptide2. These mutations result in early onset Alzheimer’s disease (EOAD), with
symptoms arising before the age of 65. Late onset AD (LOAD) often occurs without
the contribution of known genetic risk factors, but results in symptoms similar to
those of EOAD, including short term memory loss, confusion, irritability, mood
swings and eventually long term memory loss3, 4. Individuals with AD exhibit
deposition of Aβ as plaques in the brain as well as intraneuronal tangles of a highly
soluble microtubule-associated protein known as tau5. Gradually the neuronal loss
that characterizes this disease affects other bodily functions and results in death.

Cerebral Amyloid Angiopathy
Cerebral amyloid angiopathy (CAA), the deposition of Aβ along vessel walls in the
central nervous system (CNS), is a common feature of AD present in up to 94% of
AD patients6. The presence of Aβ in vessel walls in the brain has been proposed to
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result from increased Aβ production of the brains in mouse models of the disease,
as in humans with EOAD. However, in humans with LOAD, abnormal clearance of
the peptide is often thought to be the cause7. Aβ can be endocytosed by astrocytes
and microglia, support cells which function in clearing cell debris and pathogens in
the CNS8, 9. These cells, as well as neurons, express enzymes, such as neprilysin
and insulin-degrading enzyme, that allow Aβ to be degraded10. Specific clearance
across the blood brain barrier (BBB) through molecules like LRP-1 as well as
shuttling of Aβ-containing interstitial fluid along perivascular spaces have been
shown to function in Aβ removal from the brain11. Abnormalities in these removal
pathways may lead to increased CAA abundance in AD patients.

CAA has also been linked to the presence of brain microhemorrhage and even
increased risk of hemorrhagic stroke12, 13. Though it is difficult to study the effects of
CAA independent from symptoms of severe AD, as the two are often comorbid,
some studies suggest a link between CAA and cognitive decline6, 14. While some
have proposed that CAA specifically contributes to cognitive decline in AD, others
support the view that CAA simply aggravates the cognitive decline already present
due to AD15.

Cerebrovascular Dysfunction in Alzheimer’s Disease
More than 30% of AD cases exhibit cerebrovascular pathology in addition to the
CAA, microvascular degeneration, and periventricular white matter lesions (WMLs)
evident in almost all AD cases16. In fact, alterations in every cellular component of
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the neurovascular unit (NVU), the tightly regulated network of cells involved in the
coupling of neuronal energy demands to modulation of blood flow (Figure 1.1), have
been observed in AD patients. Under normal conditions, endothelial cell tight
junctions form the basis of the BBB (Figure 1.2), while pericytes regulate BBB
formation and maintenance, vascular architecture, and capillary flow17, 18. In larger
blood vessels, smooth muscle cell pulsation drives blood flow19. In AD, endothelial
cells and pericytes degenerate in brain capillaries and smooth muscle cells are lost
in larger arteries, leading to detrimental effects on neuronal perfusion and function18,
20-24

. Astrocyte endfeet, which ensheath brain capillaries (Figures 1.1, 1.2), help

regulate capillary blood flow, and maintain the extracellular milieu, are swollen in the
presence of CAA21, 22. The direct cause of these cellular abnormalities has not been
determined, though Aβ is toxic to neurons and other cell types in vitro25. Additionally,
the presence of Aβ amongst the cells of the NVU could interfere with signaling
between cell types, alter cellular health and function, and contribute to endothelial
cell degeneration resulting in reduced flow-mediated dilation, an indicator of vessel
reactivity, also observed in AD brains26. Thus, CAA may contribute to the reduced
neurovascular coupling reported in multiple AD mouse lines26-29. Furthermore, the
frequent co-incidence of stroke and AD suggests that the cerebrovascular changes
that occur during AD progression compromise vascular integrity and function30.
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Figure 1.1. Structure and function of the NVU. The NVU is the tightly regulated
network of cells involved in the coupling of neuronal energy demands to modulation
of blood flow. Endothelial cell (brown) tight junctions form the basis of the BBB and
keep blood components in the lumen (gray) from entering into the brain (light pink).
The basement membrane (yellow), a protein matrix composed of collagen, fibrillin,
laminin, integrins, entactins and dystroglycans, surrounds the endothelial cell layer.
Sandwiched within the basement membrane are pericytes (blue), which participate
in BBB formation and maintenance and in the recruitment of capillary flow.
Surrounding astrocytes (red) extend endfoot processes that serve as the outermost
layer of the capillary and help regulate capillary flow, maintain the extracellular milieu
and act as support cells for nearby neurons (purple).
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Figure 1.2. Ultrastructure of a normal brain microvessel. (A) A schematic of a
normal WT capillary in cross-section (B) highlights important morphological features
of the NVU. The endothelial cell (blue) serves as the first cell layer that separates
brain tissue from blood components. The endothelial cell tight junction is composed
of two closely associated areas of membrane that join directly due to the interaction
of transmembrane proteins. Tight junctions make the endothelial cell layer virtually
impermeable to fluid under normal circumstances and prevent blood components
within the vessel lumen (L) from entering the brain. A layer of basement membrane
(gray), a protein matrix that allows capillary cells to adhere to one another,
surrounds the endothelial cell. The pericyte (green) is sandwiched within the
basement membrane layer. The astrocyte endfoot (peach) is a cellular process that
ensheathes the capillary, providing support for NVU cells as well as aiding in
regulation of capillary flow (scale bar = 1 µm).
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Cardiovascular Disease and Alzheimer’s disease
Clinical evidence suggests that cardiovascular risk factors including atherosclerosis,
atrial fibrillation, heart disease, diabetes, and hypertension are linked to AD onset16.
In non-AD individuals, hypertension induces pathological changes in the brain such
as impaired cerebral autoregulation, vascular remodeling, cerebral microbleeds,
WMLs, lacunar infarcts, and cerebral atrophy31-34. Though midlife hypertension is a
significant risk factor for AD and treatment alleviates this risk32, 33, dramatic reduction
in blood pressure (BP) often occurs at later stages of AD, after which point
antihypertensive use is deleterious to cognitive function34, 35. It is possible that
elevated BP during midlife compromises vascular integrity and leads to cellular,
basement membrane, and/or BBB damage. However, after onset of AD symptoms,
low BP may aggravate brain hypoperfusion already present in AD due to other types
of vascular damage.

Given the vasoactive properties of Aβ36, it is unclear whether midlife hypertension is
an early symptom of the vascular pathology present in AD or if it contributes to the
onset of the disease, though there is evidence to support both views. Surgically
induced hypertension in wild type (WT) mice is sufficient to induce subtle increases
in cerebral Aβ deposition after 10 weeks37. This Aβ deposition has been shown to
result from upregulation of the receptor for advanced-glycation end products (RAGE)
at the NVU, which allows transport of Aβ from the circulation into the brain38.
Alternatively, Aβ has been shown to be vasoactive and may itself contribute to the
onset of hypertension39.
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Autophagy in Alzheimer’s Disease
Macroautophagy, referred to herein as “autophagy”, is the process by which
unnecessary or dysfunctional cytoplasmic components are degraded by
lysosomes40. Under normal conditions, autophagy is a very efficient process and
autophagosomes, containing cellular debris, or amphisomes, containing
endocytosed extracellular material, are rapidly cleared by fusion with lysosomes41
(Figure 1.3). For this reason, active autophagy is scarcely observed in tissues like
the brain42. Given that AD is a disease of excessive protein accumulation, it is not
surprising that autophagy has been found to be increased in brains of AD patients43.
Autophagy plays a central role in the pathophysiology of AD and dysfunction of this
process is deleterious to neuronal function. Interestingly, mice overexpressing
human APP and also null for the autophagy-related gene 7 (Atg7) exhibit reduced
parenchymal Aβ deposition due to inhibited Aβ secretion from cells44. However, this
reduction in Aβ deposition corresponds with increased intracellular Aβ-load and
consequent cellular damage.
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Figure 1.3. Degradation of intracellular and extracellular components by
lysosomes. Autophagy is the basic catabolic mechanism for degradation of
unnecessary or dysfunctional cellular components. Target cytoplasmic constituents
are isolated from the cytoplasm by a double-membraned vesicle known as the
autophagosome. An autolysosome, or autophagic vacuole, is formed when the
autophagosome fuses its external membrane with the membrane of the lysosome.
Endosomes, containing extracellular components imported for degradation, mature
to form multivesicular bodies (MVBs) that fuse either directly with the lysosome or
with a late autophagosome to form an amphisome. After lysosome fusion,
degradation of autophagosome, endosome or amphisome components are
mediated by acidic lysosomal hydrolases. Permeases on autolysosomal membranes
allow diffusion of degraded components back into the cytoplasm.
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Though changes in lysosomal function occur with age41, it has been proposed that
Aβ is itself the substrate of dysfunctional autophagy in AD and is also the cause45.
Autophagic vacuoles (AV), intracellular membrane-bound components bound for
fusion with lysosomes, are abundant in AD neurons46, leading some to propose that
early autophagic processes are functional in AD, but fusion with lysosomes and/or
post-autophagic clearance mechanisms are impaired42. One proposed barrier to
autophagic efficiency in AD is that autophagosomes form in synapses where
misfolded tau aggregates. Autophagosomes must undergo retrograde transport to
the cell soma, where lysosomes are most abundant, for degradation. When neurites
become damaged due to disruption of tau microfilaments, this retrograde transport is
impaired and AVs accumulate in swollen dystrophic and degenerating neurites47.
Thus the necessity for increased lysosome activity in AD paired with defective
lysosomal clearance mechanisms create conditions favorable for protein
aggregation and cellular damage.

Alzheimer’s Disease Mouse Models
Mouse models have been instrumental to the progress made in understanding and
attempting to treat AD. The identification of APP mutations in families with EOAD led
to the understanding that misprocessing of this protein was linked to disease onset.
Homologous recombination was ultimately used to insert the human APP gene,
containing known AD-causing mutations identified in EOAD families, into the mouse
genome, leading to the development of numerous mouse models and a more
aggressive study of AD in vivo. The first mouse model available for widespread use
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was the PDAPP model, which expressed transgenic human APP carrying the
Indiana mutation (V717F) under the platelet-derived growth factor (PDGF) promoter,
leading to expression of transgenic APP in neurons48. Researchers found that 40
copies of transgenic APP had integrated into the mouse genome, resulting in an 18fold elevation of APP RNA and a 10-fold elevation of human APP protein expression
compared to mouse APP49. Similar corresponding changes were observed when
levels of Aβ peptide were quantified. Furthermore, these mice exhibited Aβ plaque
deposition, neuroinflammation, learning deficits and synapse loss in an agedependent manner, all consistent with pathological changes observed in human AD
patients.

The Arctic, Australian, Austrian, Belgian, Dutch, English, Flemish, Florida, French,
German, Indiana, Iowa, Iranian, Leuven, London, Osaka, Swedish, Taiwanese and
Tottori mutations are all named after geographic locations of families carrying
specific mutations in APP that result in EOAD. Different combinations of these and
PS-1 and -2 mutations have been inserted into the genomes of mice in order to
generate models with different pathological characteristics comparable to what is
observed in humans with both EOAD and LOAD.

TgSwDI Mouse Model
Many AD mouse models have been generated since the introduction of the PDAPP
mouse model to research, each presenting with different features of AD that are of
interest to researchers. The TgSwDI mouse model is unique among other AD mouse
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models, since it represents the first model of CAA. Other AD mouse models exhibit
CAA, especially during later stages of pathological progression, but TgSwDI mice
display dramatically increased microvascular Aβ deposits relative to parenchymal
deposits in the brain 50. This mouse line carries a human APP transgene containing
three sets of EOAD mutations driven by the thymus cell antigen 1, theta (Thy1)
promoter that leads to predominant expression of transgenic APP in neurons and
some glia in the striatum and hippocampus. The Swedish mutation (Sw) results in
two adjacent amino acid substitutions (K670M/N671L) and sits at the β-secretase
cleavage site of APP, likely leading to increased cleavage of APP and thus
increased Aβ production50 (Figure 1.4). The Dutch (D) and Iowa (I) mutations
(E693Q and D694N, respectively) refer to adjacent amino acid substitutions that
likely increase deposition of Aβ along vessels rather than within in the brain
parenchyma (Figure 1.4). This mouse model exhibits dramatically increased
capillary CAA in parts of the hippocampus and the thalamus, but decreased plaque
deposition relative to other models. Additionally, the CAA in this mouse model yields
neuroinflammation and cognitive decline consistent with AD.

The TgSwDI mouse model was generated by the Van Nostrand group at Stony
Brook University and its pathology has been well characterized by members of the
group50-52. They have observed Aβ deposition in the subiculum, hippocampus and
cortex of these mice at 3 months-of-age and widespread deposition in the forebrain
by 12 months-of-age. Researchers from this group report that early microvascular
Aβ deposits are largely Aβ40 in composition. In fact Aβ40 is ten times more
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abundant in the brains of these mice than Aβ42. The length of the Aβ peptide,
typically 37-43 residues, is determined by the gamma secretase protein complex,
which cleaves Aβ at its C-terminal end53. Aβ40 is produced more readily than Aβ42
and is abundant in CAA; Aβ42 has been shown to be more fibrillogenic and more
toxic than Aβ4054, 55. Microvascular Aβ accumulation in TgSwDI mice is mostly
fibrillar and Aβ is 13-fold more abundant near microvessels than in the parenchyma.
In fact, 50% of forebrain vessels exhibit CAA. This group cites both increased
production as well as decreased clearance of mutant Aβ as the cause for increased
CAA in TgSwDI mouse brains.
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Figure 1.4. APP mutations expressed by the transgenic TgSwDI mouse line.
The TgSwDI mouse model of AD carries a human APP transgene, driven by the
neuronal Thy1 promoter, with mutations all near or within the region cleaved to form
the Aβ peptide (orange rectangle). All of the mutations in the inserted transgene
were found to be expressed by different families with EOAD. The Swedish mutation
refers to two adjacent amino acid substitutions, K670M and N671L, which lie at the
β-secretase cleavage site of APP. These mutations likely lead to increased
production of the Aβ peptide. The Dutch and Iowa mutations are adjacent
substitutions (E693Q and D694N, respectively) that increase the likelihood that the
resulting Aβ peptide will be deposited along vessels in the brain rather than in the
brain parenchyma.
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Given the largely vascular Aβ pathology in the TgSwDI mouse model and my
interest in studying the link between vascular dysfunction and AD onset, I examined
TgSwDI mice for potential effects of CAA on AD progression. I also induced chronic
hypertension in TgSwDI mice and examined behavioral, cellular, and ultrastructural
changes in order to better understand the impact of chronic hypertension on AD
pathogenesis.
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CHAPTER 2: MATERIALS AND METHODS
Animal Use
TgSwDI +/+ and C57Bl6J mice were purchased from The Jackson Laboratory and
bred in house to generate the mice used for experiments described in Chapter 3.
TgSwDI +/- and -/- littermates were generated using in vitro fertilization (IVF) at the
Transgenic Services Laboratory at The Rockefeller University and were used to
conduct the experiments described in Chapter 6. Both TgSwDI +/+ and +/- animals
as well as either C57Bl6J or TgSwDI -/- controls were used for experiments
described in Chapters 4 and 5. For this reason, a Table listing the genotypes of AD
and WT groups for each set of experiments described herein has been included for
reference (Table 2.1). Genotypes were determined by PCR on tail samples taken
before weaning. TgSwDI +/+ or +/- mice were considered AD animals, and C57Bl6J
or TgSwDI -/- mice were used as WT controls. When described, TgCRND8 +/- and
Tg6799 +/- were also considered AD and TgCRND8 -/- and Tg6799 -/-, respectively,
were used as WT controls. All mice were maintained on a 12-hour light/dark cycle
with food and water provided ad libitum and mice of both sexes were used in
approximately equal ratios for all experiments, except when otherwise specified
(Table 2.1). All animal procedures were approved by the Institutional Animal Care
and Use Committee at The Rockefeller University.
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Table 2.1. AD and WT cohort details by experiment.
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Genotyping
The presence of the TgSwDI transgene was assessed in DNA preparations from tail
samples of TgSwDI +/- and -/- using primers against the transgene and an internal
control gene (oIMR5260, 0IMR5261, oIMR1544, oIMR3580; The Jackson
Laboratory) and the following polymerase chain reaction (PCR) conditions: 3
minutes at 94°C; 30 seconds at 94°C, 1 minute at 52°C, and 1 minute at 72°C,
repeated for 35 consecutive cycles; 2 minutes at 72°C.

Statistics
All numerical data are presented as mean ± standard error of the mean. Statistical
significance of data collected over time (BP, Barnes maze performance curves) was
determined using a two-way ANOVA with a Bonferroni post-hoc correction. In all
other cases, statistical significance was determined using a 2-tailed Student’s t-test
comparing different experimental groups. p-values <0.05 were considered
significant.

Y-maze
Mice were allowed to freely explore an open-armed Y-shaped maze for 5 minutes in
low lighting (50 lux). The order of arm entry was scored and alternation was
determined by dividing the number of arm entry triads (all three arms visited
subsequently) by the total number of arm visits minus 256. Percent alternation was
compared between groups. For this and all subsequent behavior tests described,
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scoring was conducted by an experimenter who was blind to the genotype and to the
treatment and age (when relevant) of all animals.

Barnes Maze
The Barnes maze apparatus (TAP Plastics) consisted of a white circular platform 92
cm in diameter with 20 equally spaced holes, each 5 cm in diameter and 7.5 cm
apart. Of these holes, 19 were blocked with black plastic and 1 (target hole) was
routed to a black escape box that was secured below the surface of the table. Distal
visual cues consisting of black and white geometric shapes were placed throughout
the testing room, and ambient lighting was kept high (1500 lux) to motivate animals
to find and enter the escape box. During training, mice were allowed to search the
maze for the target hole for 2 minutes, after which time they were guided to the
target hole. Training consisted of 1 trial per day for each mouse for 4 consecutive
days. On the fifth day, a probe trial was carried out to assess spatial memory of the
mice (24-hr probe trial) 57. The target hole was blocked off with black plastic, and the
mice were allowed to explore the maze for 90 seconds while their behavior was
recorded. An extended probe trial was held five days later (5-d probe trial). All trials
were recorded and scored for latency to find the target hole (first nose poke) as well
as latency to enter the target hole using Ethovision software (Noldus). Velocity,
distanced traveled, and number of entries into the area around the target hole were
determined and compared between groups.
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Contextual Fear Conditioning
Fear conditioning experiments were run in a conditioning chamber (MedAssociates)
equipped with a light and an overhead video camera and all trials were recorded for
subsequent scoring. On the first day of the test, mice were placed in a conditioning
chamber that had been cleaned with 70% ethanol and were allowed to habituate to
the chamber for 2 minutes. Animal behavior during these first 2 minutes was used to
assess baseline freezing behavior. Mice then received 2 foot shocks (0.7 mA for 2
seconds each), one minute apart. Mice were removed from the chamber 30 seconds
after the last foot shock. After 24 hours, each mouse was placed into the same
chamber in which it received foot shocks the previous day and allowed to explore
the chamber for 5 minutes while its movements were recorded. Freezing behavior
for all trials was scored in 5-second bins and was taken to indicate a mouse’s
memory of the foot shocks from the previous day58.

Porsolt Swim Test
Each mouse was placed in a 4-L transparent beaker filled to 80% capacity with room
temperature water. The final water level was 5 cm below the mouth of the beaker, so
mice were not able to attempt escape. Mobility of each mouse in the water was
observed for 6 minutes and all trials were video recorded for later analysis59. Animal
movement was scored manually every 5 seconds and immobility was defined as
lack of movement, except for that which was required to keep the animal afloat. The
total time spent immobile over the course of the trial was compared between groups.
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Fixed Immunohistochemistry
Mice were heavily anesthetized by IP injection of 1 mL 2.5% tribromoethanol and
perfused with 5 mL 0.9% saline followed by 15-30 mL 4% paraformaldehyde (PFA)
according to body weight. Brains were post-fixed overnight in 4% PFA and
cryoprotected for 24 hours in 30% sucrose in 0.1 M phosphate buffer at 4°C. Brains
were then frozen on powdered dry ice and sliced into 30-micron coronal sections
using a microtome. Sections were collected into freezing medium (30% glycerol,
30% ethylene glycol, 40% 0.1 M phosphate buffer) and stored at -20°C until use.
Hippocampus-containing free-floating brain sections were mounted on glass slides
using a gelatin-based mounting medium and dried overnight at room temperature.

Slides were rinsed upright in 1X PBS for 5 minutes before undergoing antigen
retrieval. Antigen retrieval conditions were determined for each antibody (Table 2.2)
and included no treatment, incubation in Proteinase K (Dako) and/or boiling in
sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20 in ddH2O, pH 6.0).
Slides were rinsed 3 times for 5 minutes each in 1X PBS and blocked in 3% normal
donkey serum with 0.3% Triton X-100 in 1X PBS for 1 hour at room temperature.
Antibodies were diluted in blocking buffer at concentrations ranging from 1:1001:10,000 and sections were incubated in primary antibody solution for 12-18 hours at
room temperature and then washed in 1X PBS 3 times for 5 minutes each. Sections
were incubated in fluorescently-labeled secondary antibody (Alexa Fluor, donkey
anti-host species, 1:200) for 1-2 hours at room temperature, then washed and
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covered using ProLong Gold antifade reagent (Life Technologies) and microscope
cover glass (Fisher).

Sections were visualized using an Axiovert 200 inverted epifluorescence microscope
or an LSM510 laser scanning confocal microscope (Carl Zeiss, Inc.). All sections
were imaged at 20x-40x magnification. Exposure time and gain were consistent for
each stain between all sections from all animals.
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Table 2.2. Antibodies used for immunohistochemical studies.
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Fresh Immunohistochemistry
Mice were heavily anesthetized by IP injection of 1 mL 2.5% tribromoethanol and
perfused with 15-30 mL 0.9% saline according to body weight. After perfusion,
brains were removed and immediately covered in powdered dry ice. Brains were
stored at -80°C until slicing into 30-micron coronal sections using a cryostat. Tissue
sections were thaw-mounted directly onto glass slides and stored at -80°C until use.
Staining was carried out as in “Fixed Immunohistochemistry”, but with brief fixation
using 4% PFA or ethanol (Table 2.2) and without antigen retrieval.

Thioflavin S Staining
Hippocampus-containing fixed free-floating coronal brain sections were mounted
onto glass slides using a gelatin-based mounting medium and dried overnight at
room temperature. Slides were rinsed in 1X PBS and immersed in Thioflavin S
(ThioS) solution (0.02% Thioflavin S dissolved in ddH2O and filtered, Sigma-Aldrich)
for 30 minutes at room temperature. Slides were then immersed in 70% ethanol for
15 minutes, washed and covered using ProLong Gold antifade reagent (Life
Technologies) and microscope cover glass. Z-stacks containing 5 images, each 1
µm apart, were collected for each hippocampal subregion at 25X magnification using
an inverted LSM510 laser scanning confocal microscope (Carl Zeiss, Inc.). Exposure
time and gain were consistent between all sections from all animals.
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Evans Blue Extravasation Assay
A solution of 2% Evans blue (Sigma-Aldrich) in 0.9% saline was injected (10 mL/kg
body weight) intraperitoneally (IP) into each mouse. 24 hours after injection, mice
were heavily anesthetized by IP injection of 1 mL 2.5% tribromoethanol and
perfused transcardially with 0.9% saline to remove the intravascular dye. Brains
were frozen immediately on powdered dry ice and kept at -80C until sectioning.
Brains were sectioned coronally at 30 microns using a cryostat and Evans blue
extravasation was assessed directly by analysis of fluorescence in hippocampal
subregions at 20x-40x magnification.

L-NAME-Induced Hypertension
Mice were weighed and divided into cages according to treatment type. Water
consumption per cage was quantified over a 7-day period and Nω-Nitro-L-arginine
methyl ester hydrochloride (L-NAME, Sigma-Aldrich) was diluted into drinking water
so that each mouse consumed approximately 100 mg/kg body weight per day.
Treatment was initiated at 3-4 months-of-age and continued for 3 or 6 months.

Angiotensin-II and L-NAME-Induced Hypertension
Mice were anesthetized by IP injection of 2.5% tribromoethanol (500 mg/kg body
weight) and atropine (0.04 mg/kg body weight) and osmotic infusion pumps (Alzet)
were implanted subcutaneously at the scruff of the neck to deliver 1 µg/kg body
weight per minute angiotensin II (Ang-II, Sigma-Aldrich) dissolved in sterile 0.9%
saline. Surgical incisions were stitched closed using 6-0 silk sutures (Harvard
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Apparatus). Following surgery, mice were injected IP with buprenorphine HCl (0.03
mg/kg body weight) and 500 µL sterile 0.9% saline and allowed to recover on a
heating pad. Additionally, L-NAME was delivered as described in “L-NAME-induced
Hypertension”.

Tail Cuff Plethysmography
BP was measured one week prior to and every week during Ang-II and/or L-NAME
treatment by tail cuff plethysmography according to the manufacturer’s instructions
(Kent Scientific). Mice were placed in a restrainer and rested on top of a heating pad
to keep body temperature around 37°C. Three BP readings were obtained and
averaged for each animal.

Stereology
Images of hippocampal subregions (Figure 2.1), the dentate gyrus (DG), the dorsal
subiculum (DS), cornu ammonis 1 (CA1) and cornu ammonis 3 (CA3), from
immunostained tissue were quantified using NIH Image J software. Hippocampus
subregions were identified and outlined. Stained images were split into their
component red, green and blue color channels, and the channel containing signal
was selected for further processing. Images were thresholded manually to yield
intensity in the areas containing apparent signal but not in background. Signal value
was normalized to the size of the area from which it was extracted. For “vessel
coverage” quantifications, stretches containing pixels of both the marker of interest
and a vascular marker were selected using the line selection tool, added and
25

normalized to the size of the region quantified. Signal intensity, item number and
pixel length was analyzed for each subregion and then compared between groups.
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Figure 2.1. Anatomical map of hippocampal subregions. The hippocampus
coordinates memory consolidation and spatial navigation and is one of the first
regions in the brain to suffer damage in humans with AD and in the TgSwDI mouse
model of AD. Hippocampal subregions are depicted here in a schematic of a coronal
section through the hippocampus. The DG (green) receives excitatory inputs from
the entorhinal cortex (not shown) and projects to pyramidal cells in the CA3 (light
blue) via the mossy fiber tract. The DG is thought to be involved in pattern
separation, as it converts similar inputs to substantially different outputs.
Behaviorally, it contributes to the formation of new episodic memories and
spontaneous exploration of novel environments. Additionally, the neurogenesis that
happens in the DG contributes to spatial memory formation. Schaffer collaterals
connect the CA3 to the CA1 (dark blue). The CA1 has been proposed to perform
match-mismatch roles in the hippocampus, comparing memory retrieval with
sensory input. CA1 cells synapse in the subiculum (dorsal subiculum, red) for relay
out of the hippocampus. The subiculum is implicated in working memory and
processing of spatial relationships, as well as the spread of Aβ to other hippocampal
and non-hippocampal brain regions in AD.
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Immunoelectron Microscopy
Mice were heavily anesthetized by IP injection of 2.5% tribromoethanol and were
perfused with 0.9% saline followed by 15-30 mL 4% PFA according to body weight
at slow speed. Brains were removed, immersed in 4% PFA, and sliced into 50-µm
sections using a Leica VT 1000S vibrating blade microtome. The dorsal subiculum
was removed and frozen in liquid nitrogen under high pressure using a Leica EM
PACT2. Freeze substitution was performed using a Leica AFS2 automatic freeze
substitution unit60. Tissue was sectioned at 90 nm onto carbon-coated copper mesh
grids. After drying, grids were rinsed in 20 mM HEPES, pH 7.5, blocked with 3%
bovine serum albumin (BSA) and 0.1% saponin in 20 mM HEPES, pH 7.5 for 2
hours at room temperature and incubated in primary antibody (1:900-1:32,000) at
4°C overnight (Biosource). Grids were then washed, incubated in blocking solution
for 5 minutes, and incubated in 12-nm gold anti-host species secondary antibody
(Jackson ImmunoResearch) in a solution containing 0.5% BSA, 0.1% saponin, and
20 mM HEPES, pH 7.5, for 1 hour at room temperature. After washing and fixing in
2.5% glutaraldehyde for 3 minutes, tissue sections were imaged using a JEOL
100CX transmission electron microscope at 80 kV. All post-perfusion steps were
conducted at The Rockefeller University Electron Microscopy Resource Center
(EMRC).

Transmission Electron Microscopy
Mice were heavily anesthetized by IP injection of 2.5% tribromoethanol and were
perfused with 0.9% saline followed by 15-30 mL 4% PFA according to body weight
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at a slow speed. Brains were removed and sliced using a brain matrix into 1-mm
thick coronal sections. Sections were then immersed in 2.5% glutaraldehyde in 0.1
M sodium cacodylate buffer with 2 mM CaCl2 at 4°C for 24 hours. Sections were
immersed in 0.1 M sodium cacodylate buffer at 4°C for 24 hours and the dorsal
subiculum was isolated. Tissue was post-fixed with 1% osmium tetroxide and 0.51.5% potassium ferrocyanide in 0.1 M sodium cacodylate buffer for 1 hour on ice.
Tissue was washed once in 0.1 M sodium cacodylate buffer and twice in ddH2O and
stained in 1% uranyl acetate for 30 minutes at room temperature. Tissue was then
quickly washed in water and dehydrated in increasing concentrations of ethanol
(70%, 80%, 95%, 100%, 100%, 100%), followed by propylene oxide for 10 minutes
each at room temperature. Propylene oxide was replaced with two exchanges of
EMbed812 resin and tissue was placed under vacuum for 24 hours at room
temperature. The resin was exchanged three more times over the following 24
hours and kept under vacuum before samples were cured in resin for 48 hours at
60°C. The tissue was sliced at 60-80 nm using a Leica Ultracut E and visualized
using a JEOL 100CX transmission electron microscope at 80 kV. All post-perfusion
steps were conducted at the Rockefeller University EMRC.

3View
Mice were heavily anesthetized by IP injection of 1 mL 2.5% tribromoethanol and
perfused with 5 mL 0.9% saline followed by 15-30 mL 4% PFA according to body
weight at slow speed. Brains were removed, immersed in 4% PFA, sliced into 100µm sections using a Leica VT 1000S vibrating blade microtome and the dorsal
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subiculum was removed and immersed in 4% PFA and 2.5% glutaraldehyde in 0.1
M sodium cacodylate buffer with 2 mM CaCl2 overnight. The tissue was washed and
incubated in 1.5% potassium ferrocyanide, 2% osmium tetroxide in 0.1 M sodium
cacodylate buffer with 2 mM CaCl2 for 1 hour on ice. Tissue was then washed with
room temperature ddH2O and incubated in filtered 0.1% thiocarbohydrazide solution
in ddH2O for 20 minutes. After rinsing, the tissue was re-exposed to 2% osmium
tetroxide for 30 minutes, washed and incubated in aqueous 1% uranyl acetate for
12-18 hours. The tissue was stained in aqueous 20 mM lead nitrate and 30 mM
aspartic acid, pH 5.5, at 60C for 30 minutes. After washing, the tissue was
dehydrated in increasing concentrations of ethanol (20%, 50%, 75%, 100%, 100%,
100%) in a Pelco Biowave at 10C and 150 watts for 40 seconds each, then placed in
ice-cold acetone for 10 minutes, followed by room temperature acetone for 10
minutes. Increasing concentrations of durcupan resin in acetone was infiltrated into
samples using a Pelco Biowave (25%, 50%, 75%, 100%, 100%) and left to infiltrate
under vacuum overnight. Samples were embedded between sheets of aclar and
cured at 60°C for 48 hours. After mounting, blocks were trimmed and sputter coated
for 120 seconds using gold/palladium (Denton). The tissue surface was imaged
every 50 nm for 25 µm using a MERLIN scanning electron microscope (Carl Zeiss,
Inc.) and processed using Gatan 3View System software.

Western Blotting
Fresh hippocampi or dorsal subiculum samples were dissected on ice and
homogenized in lysis buffer (25 mM Tris-HCl, pH 7.6; 150 mM NaCl, 1% NP-40, 1%
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sodium deoxycholate, 0.1% SDS) with protease and phosphatase inhibitors added
(Sigma-Aldrich, Roche) and sonicated on ice. After large cellular debris was
removed from samples by centrifugation, protein concentration was determined by
spectrophotometry using a bicinchoninic acid (BCA) kit (Thermo Scientific) according
to the manufacturer’s instructions. Loading dye with β-mercaptoethanol was added
to the samples, which were then boiled for 5 minutes at 100C. 20-30 µg of protein
were loaded per lane and samples were run on a denaturing 8% Tris-Glycine gel,
transferred to a nitrocellulose membrane and blocked in a 5% milk and 3% BSA
solution dissolved in Tris-buffered saline with 0.5% Tween 20. Blots were probed
with antibodies (1:1000-1:2000) in blocking buffer at 4°C overnight and washed.
Blots were then incubated with the appropriate HRP-labeled secondary antibody
(1:5000-1:10,000) in blocking buffer, washed again, incubated in chemiluminescent
reagent (PerkinElmer) and exposed to film. Band intensity was quantified using NIH
ImageJ software and normalized to actin from the same blot.

Hypoxyprobe Detection
A solution of 60 mg/kg body weight pimonidazole HCl (dissolved in sterile 0.9%
saline, Hypoxyprobe) was injected IP into each mouse. 60 minutes after injection,
the mice were heavily anesthetized by IP injection of 1 mL 2.5% tribromoethanol and
perfused transcardially with 15-30 mL 0.9% saline according to body weight. Brains
were removed and frozen immediately on powdered dry ice and kept at -80°C until
sectioning. Brains were sectioned coronally at 30 microns onto glass slides using a
cryostat and stored at -80°C until use. Slides were then incubated in FITC-MAb1
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according to the manufacturer’s instructions. Hippocampal subregions within stained
sections were imaged at 20-40x magnification.
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CHAPTER 3: CHARACTERIZATION OF ALZHEIMER’S NEUROPATHOLOGY IN
THE TGSWDI MOUSE MODEL
Cognitive Decline
Cognitive decline was examined in TgSwDI mice by a variety of behavioral tests.
Given that previous publications reported cognitive decline in TgSwDI mice at 3
months-of-age52, but had not yet tested younger mice (W. Van Nostrand, personal
communication), TgSwDI mice were tested for learning and memory impairments at
2, 3 and 6 months-of-age. Though 2-, 3- and 6-month-old TgSwDI mice exhibited no
differences in spontaneous alternation using the Y-maze test or expression of
learned fear after fear conditioning, 6-month-old TgSwDI mice did exhibit a reduced
preference for the target hole (Figure 3.1A) during the 5-d probe trial in the Barnes
maze, a test of spatial learning and memory57, when compared to age-matched WTs
(Figure 3.1B). Thus the earliest detectable indication of cognitive decline in this
colony of TgSwDI mice occurred at 6 months-of-age.
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Figure 3.1. TgSwDI mice exhibit cognitive deficits at 6 months-of-age. (A) The
Barnes maze tests spatial learning and memory. Mice were trained to find the
location of a target hole (red) that led to a hidden escape box (blue) based on visual
cues around the maze and were tested for their learned preference for the area near
the target hole after training. (B) At 6 months-of-age, TgSwDI mice exhibited no
preference for the target hole during the 5-d probe trial, compared to WT mice
(p<0.05). TgSwDI also exhibited reduced preference for the hole adjacent to the
target hole (hole number 20) compared to controls (p<0.05).
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Amyloid Deposition
Compared to WT mice and 2-month-old TgSwDI mice, which exhibited no Aβ
deposition in the brain by ThioS staining, TgSwDI mice exhibited more Aβ in the
hippocampus starting at 3 months-of-age (Figure 3.2). TgSwDI mice exhibited a
small amount of Aβ in the DS and DG regions of the hippocampus at 3 months-ofage, though the deposition appeared in small plaque-like patches (Figure 3.2B). By
6 months-of-age, ThioS staining revealed abundant CAA and decreased presence of
parenchymal plaques relative to earlier time points (Figure 3.2C vs. 3.2A,B).
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Figure 3.2. Pattern of Aβ deposition over time in TgSwDI mice. Deposition of Aβ
in the DS was examined in 2- (A), 3- (B), and 6-month-old (C) TgSwDI mice by
ThioS staining (green). Anti-collagen IV co-staining (red) was used to identify
capillaries. At 2 months-of-age, TgSwDI mice exhibited little-to-no ThioS-positive
signal in the DS (A), whereas small diffuse plaques were observed by 3 months-ofage (B). At 6 months-of-age, parenchymal plaque-load was reduced and Aβ was
abundant along capillaries in the brain (C; scale bar = 50 µm).
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Gliosis
Microglia activation in TgSwDI mice was determined by abundance of microglia
compared to WT (Figure 3.3). Microglia were stained using a fluorescently-labeled
tomato isolectin, a sugar-binding glycoprotein with specific affinity for poly-N-acetyl
lactosamine residues present on the surface membranes of microglia and
endothelial cells61. Positive signal was determined to be microglial rather than
endothelial based on morphology of stained cells. TgSwDI mice (Figure 3.3D-F)
exhibited more microglia-like staining at 2, 3 and 6 months-of-age in the DG and DS
compared to WT mice that exhibited no observable microgliosis at these ages
(Figure 3.3A-C). Importantly, this result demonstrates that microgliosis preceded
both Aβ deposition as plaques, which occurred at 3 months-of-age in TgSwDI mice,
and as CAA, which occurred at 6 months-of-age (Figure 3.2).
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Figure 3.3. Microgliosis precedes Aβ deposition in TgSwDI mouse brains.
Fluorescently-labeled tomato isolectin (green) is a sugar-binding glycoprotein with
specific affinity for sugar residues on microglial and endothelial cell surfaces.
Stained endothelial cells and microglia are morphologically distinct; capillary
endothelial cells were present in all images and appeared as thin streaks, while
microglia appeared as large patches of dense signal. The increased appearance of
microglia in the DS of 2- (D), 3- (E), and 6-month-old (F) TgSwDI mice compared to
WT mice of the same ages (A, 2-months; B, 3-months; C, 6-months-old) indicate
that microglia were activated in TgSwDI brains as early as 2 months-of-age.
Microgliosis becomes apparent in the DG of TgSwDI mice around 6 months-of-age,
later than in the DS (F vs. D, scale bar = 100 µm).
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BBB Integrity
The Evans blue injection model was used to determine the age at which TgSwDI
mice first exhibited BBB breakdown (Figure 3.4). When injected IP, the azo dye
Evans blue (red) enters the blood stream and binds to albumin with high affinity.
Under normal conditions, the plasma protein albumin (65 kDa) is too big to cross the
BBB and is removed during perfusion along with the associated Evans blue. In the
case of a leaky BBB, however, albumin carries Evans blue into the brain
parenchyma where it can be detected by fluorescence microscopy. After injection,
Evans blue was detected in the cortex and hippocampus of 3-month-old TgSwDI
mice (Figure 3.4B), but not in 2-month-old TgSwDI mice (not shown) or WT mice at
any age examined (up to 12 months; Figure 3.4A). By 12 months-of-age, Evans blue
leakage in the brains of TgSwDI mice was prominent (Figure 3.4D).

41

Figure 3.4. TgSwDI mice exhibit early BBB breakdown. Evans blue was injected
into TgSwDI and WT mice of different ages (A-D). 18 hours after injection, mice
were perfused with saline and their brains removed. Imaging revealed the presence
of Evans blue in the DS of TgSwDI mice as early as 3 months-of-age (B). Evans
blue leakage was severe at 6 (C) and 12 months-of-age (D) in TgSwDI mice
compared to WT mice at 12 months-of-age (A), where little-to-no signal was
observed (scale bar = 50 µm).

42

Autophagy
Lysosomal-associated membrane protein-1 (LAMP-1) was used as an autophagic
marker since it is present on both lysosomal and endosomal membranes62 (Figure
3.5). LAMP-1 is often increased at dysfunctional synapses in AD, as AVs are known
to build up in dystrophic neurites in the brain46. LAMP-1 signal was evident in the DS
of TgSwDI mice as early as 3 months-of-age (Figure 3.5B), the earliest age
examined. By 6 months-of-age, LAMP-1 staining was evident in the DS and DG
(Figure 3.5C) as well as the thalamus (not shown), suggesting that pathology was
not only more severe at this age, but also more extensive. Though LAMP-1
immunostaining is typically used to indicate synaptic dysfunction in AD mice, it is
possible that other cell types in the brain were responsible for the observed increase
in LAMP-1 staining, as no cell type-specific co-stain was used. LAMP-1 signal
became more diffuse in the DS at 6 months-of-age, possibly coincident with the
transition from Aβ deposition as plaques to CAA (Figure 3.2).
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Figure 3.5. TgSwDI mice display evidence of increased autophagy. LAMP-1, a
protein present on lysosomal and endosomal membranes, was examined in TgSwDI
and WT brain tissue using an anti-LAMP-1 antibody (A-C). At 6 months-of-age, no
LAMP-1 was detectable in the hippocampus of WT mice (A). In TgSwDI mice at 3
months-of-age, LAMP-1 appeared as small clusters in the DS of the hippocampus
(B). LAMP-1 staining was also present as clumps in the DG and CA1 in TgSwDI
mice at 6 months-of-age (C). The LAMP-1 signal in the DS at this time point was
more widespread, though large patches were no longer apparent (scale bar = 100
µm).
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Differences in Depressiveness, Anxiety and Locomotion in TgSwDI Mice
Researchers who generated the TgSwDI mouse line report early cognitive deficits,
but no changes in balance, locomotion or anxiety52. However, TgSwDI mice from the
colony I examined exhibited significant differences in defecation, an indication of
anxiety level in mice, in a number of behavioral tests during testing for onset of
cognitive decline (Figure 3.6). During Barnes maze testing, TgSwDI mice exhibited
increased defecation at all ages (Figure 3.6A-C), a finding that was similar during
fear conditioning (Figure 3.6D). TgSwDI mice also exhibited increased learned
helplessness at 3 months-of-age on the Porsolt swim test (Figure 3.6E). Together,
these findings suggest differences in emotionality in TgSwDI mice compared to WT
mice, independent of cognitive decline, which was only detectable at 6 months-ofage (Figure 3.1).
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Figure 3.6. TgSwDI mice exhibit increased anxiety- and depressive-like
behaviors. (A-C) During Barnes maze training, TgSwDI mice defecated more than
age-matched WT control mice at 2 (A), 3 (B) and 6 months-of-age (C; *p<0.05,
**p<0.01). Defecation is an indication of anxiety in mice and decreased gradually
over the course of Barnes maze training in most groups. (D) During fear
conditioning, defecation decreased with age in WT mice, but remained elevated in
TgSwDI mice at 2, 3 and 6 months-of-age (*p<0.05, **p<0.01). (E) The Porsolt swim
test is used to examine depressive-like behavior in mice. A reduced latency to
immobility is known as “learned helplessness”, a behavioral output that is similar to
some features of depression in humans. TgSwDI exhibited shorter latencies to
immobility at 3 months-of-age compared to age-matched WT controls (E, *p<0.05).
This trend persisted at 6 months-of-age (not shown).
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TgSwDI mice also exhibited reduced mobility in multiple behavioral tests relative to
WT mice (Figure 3.7). During Y-maze testing, TgSwDI mice were consistently less
mobile than WTs at 2, 3 and 6 months-of-age (Figure 3.7A). During Barnes maze
testing, TgSwDI mice exhibited an age-dependent reduction in mobility (Figure
3.7B). Given these results, it is unclear whether the decreased latency to immobility
observed in TgSwDI mice at 3 months-of-age during the Porsolt swim test (Figure
3.6E) represents increased depressiveness in the animals or is an artifact of their
reduced locomotion.
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Figure 3.7. TgSwDI mice exhibit reduced mobility. During behavioral testing for
cognitive decline, TgSwDI mice demonstrated reduced mobility in the Y-maze (A)
and Barnes maze (B) tests compared to age-matched WT controls. Mobility was
reduced in this mouse line at both 3 and 6 months-of-age using both tests (A,B;
*p<0.05, **p<0.01, ***p<0.001). At 2 months-of-age, TgSwDI mice only exhibited
reduced locomotion during Y-maze testing. Given that increased latency to
immobility was observed at 3 months-of-age during the Porsolt swim test, it is
possible that the Porsolt swim test result is suggestive of motor differences, rather
than a depressive-like phenotype in TgSwDI mice.
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TgSwDI Background Characterization
Since the TgSwDI mouse model was generated on a pure C57Bl6J background50,
C57Bl6J mice were initially used as controls. This method was beneficial, since
frequent genotyping and separation of mice were not required during breeding.
Additionally, TgSwDI mice were used as homozygotes and two copies of the
transgene resulted in earlier and more severe pathology and both TgSwDI and
C57Bl6J mice could be ordered to supplement experiments if breeding was slow.
However, after establishing that the behavior of this colony of TgSwDI mice was
inconsistent with published reports52 (Figures 3.1, 3.6, 3.7), DNA samples from two
of eight colony founder mice were sent for background characterization to determine
if C57Bl6J was the correct control based on the background of the TgSwDI mice
from this colony.

An initial 384 SNP background strain characterization test (Charles River) indicated
that both founder animals were mostly C57Bl6J (99.73% and 99.61%). However,
both animals were found to be heterozygous for a marker on chromosome 10 in a
region polymorphic between C57Bl6J and C57Bl6N substrains, indicating that the
TgSwDI mice from this colony had a mixed C57Bl6 background.

Though C57Bl6 substrains arose from the same mouse line, decades of breeding in
separate facilities have resulted in subtle genomic divergence63. Two spontaneous
mutations have arisen in coding sequence DNA since the two lines have been bred
separately. The Crb1 gene contains a 1bp deletion in C57Bl6N mice compared to
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C57Bl6J and a deletion in the Nnt gene can now be found in C57Bl6J mice. Though
these differences are seemingly inconsequential, other groups have reported
behavioral differences between C57Bl6J and N substrains64. Further analysis on
colony founder DNA involved the examination of 15 microsatellite markers showing
polymorphism between C57Bl6 substrains (Charles River). Microsatellite marker
testing showed that both founder mice had slightly more C57Bl6J in their genetic
backgrounds than C57Bl6N (62.5% and 65.62%). The unique differences between
the founders at these microsatellite sites are listed in Table 3.1. The importance of
the D2Mit277, D6Mit116, D11Mit71, and D18Mit49 loci, which were different in the
two founders, are not known, as these regions have not been studied in detail. The
Nnt gene, which was polymorphic between the two founders, encodes a
mitochondrial NAD(P) transhydrogenase. This integral inner mitochondrial
membrane protein couples hydride transfer between NAD(H) and NADP(+) to proton
translocation across the inner mitochondrial membrane. The importance of this
polymorphism is unclear, since the effect of each polymorphism on gene product
production and function is not known.
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Table 3.1. Mixed background of TgSwDI mice.
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Use of Homozygotes vs. Heterozygotes
Due to the mixed background observed in the colony of TgSwDI mice being studied
and the potential effects of strain background on behavioral characteristics in mice,
TgSwDI mice were crossed with C57Bl6J mice to generate TgSwDI +/- and -/- for
future use. Though the background would still be mixed for these mice, the
background would be similarly mixed in the littermates used as controls.

Importantly, preliminary studies conducted on this mouse line (Figures 3.1-3.7)
employed TgSwDI homozygotes. The new breeding and genotyping scheme would
require the use of heterozygotes. The onset and severity of pathology is likely to
vary between homozygotes and heterozygotes and previously published reports on
this mouse line describe experiments done with homozygotes. Thus findings in
heterozygotes are likely to be less severe at any given time point due to expression
of one copy of transgenic APP rather than two.
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CHAPTER 4: INDUCING HYPERTENSION IN TGSWDI MICE
Assessment of Methods for Inducing Hypertension in Mice
Surgical, genetic and chemical techniques have been developed to induce
hypertension in rodent models for research. Surgical models entail the ligation of the
renal artery or abdominal aorta, or removal of one kidney. All of these techniques
result in reduced kidney function. Since the kidneys regulate the amount of fluid in
the body as well as arterial constriction and damaged kidneys often overproduce
renin, these techniques increase arterial constriction and result in high BP. The
transverse aortic constriction (TAC) model has also been used for studying the
effects of hypertension on the brain and heart65. TAC, which involves ligation of the
transverse aorta, causes increased BP and blood volume in the vasculature leading
up to the point of constriction, which includes the right carotid artery as well as the
heart.

Ultimately, surgical techniques for inducing hypertension were avoided, because
wounds resulting from surgical techniques are susceptible to infection or injury.
Wounded mice often require single-housing so that they are protected from fighting
with other mice as well as easily monitored while they heal. Social isolation in mice
in turn results in altered behavior in a number of behavior tests and has even been
shown to exacerbate AD pathology66-68. Thus, surgically-induced hypertension was
likely to result in experimental artifacts based on housing conditions and/or a smaller
experimental cohort.
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Genetic models of hypertension involve overexpression of WT or transgenic renin,
resulting in increased circulating Ang-II. Ang-II stimulates vascular smooth muscle
cells and results in their contraction69. Ang-II also stimulates ion exchange in the
kidneys resulting in increased blood volume, BP and blood pH70. In fact, Ang-II is so
effective at increasing BP that angiotensin converting enzyme (ACE), the enzyme
required for production of Ang-II, is the target of a major group of antihypertensive
drugs, the ACE inhibitors71. Angiotensin receptor blockers (ARBs) or Sartans,
another group of commonly used antihypertensive drugs, are effective due to their
action in preventing Ang-II binding to receptors72. Genetic models to induce
hypertension were not ideal, since AD mouse models can be weak when crossed to
other strains. Often the mixture of the genetic background is important to the survival
of a strain when a deleterious transgene, such as mutated APP, is inserted into the
genome. Changing the background of a strain can result in changes in litter size,
pup survival and birth rates. Also, generating a double-transgenic mouse colony
often requires many months to achieve cohorts large enough for experimentation,
even when adjusting the genetic background of the strain has no impact on
reproduction and survival of the mice.

Finally, chemical models of hypertension involve administration of chemical
components of the pathway that regulates BP endogenously and/or chemicals that
regulate the production of pathway components. Direct Ang-II administration is one
example of this. Ang-II treatment can be paired with administration of L-NAME to
provide a two-pronged approach to increasing BP73. Chemical models are useful
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since treatment can be adjusted to yield more or less severe hypertension.
Treatments are also often easy to administer or withhold from mice at different time
points, depending on experimental requirements, which is not true for surgical or
genetic models.

Ang-II and L-NAME-Induced Hypertension in AD Mouse Models
Ang-II is a component of the endogenous renin-angiotensin system, which controls
BP in mammals. The serum globulin angiotensinogen is produced in the liver and
released into the circulation, where it becomes activated by renin to form angiotensin
I. Angiotensin I is converted to Ang-II by ACE. Ang-II is a potent vasoactive peptide
and, because it causes vasoconstriction, it can independently raise BP when
delivered subcutaneously.

L-NAME supplementation of Ang-II treatment has been described as a useful
technique for inducing hypertensive intracerebral hemorrhage (ICH) in rodents73. LNAME is an endothelial cell nitric oxide synthase (eNOS) inhibitor. Nitric oxide
synthases (NOS) catalyze the production of nitric oxide (NO) from L-arginine
endogenously. NO is an important cellular signaling molecule and also modulates
vascular tone, insulin secretion, peristalsis, angiogenesis and neural development74.
It also functions in the brain as a retrograde neurotransmitter75. Three forms of NOS
are produced endogenously: eNOS, which is produced by endothelial cells; nNOS,
which is produced by neurons; and iNOS, or inducible NOS, which increases levels
of NO as an immune defense against pathogens. L-NAME causes vasoconstriction
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by selective inhibition of eNOS, which is produced by the vascular endothelium to
induce vasodilation. Therefore, L-NAME directly inhibits the ability of the
endothelium to dilate and relieve spikes in BP caused by physiological changes,
such as increased levels of Ang-II.

Ang-II infusion along with L-NAME administration were used in early attempts to
increase BP in 3 different mouse models of AD used in the lab: TgSwDI, Tg6799
and TgCRND8. However, Ang-II and L-NAME administration together resulted in
seizures and increased mortality shortly after initiation of treatment in all three
mouse lines (Figure 4.1A). Additionally, the use of this model for induction of ICH by
other groups was worrisome73, since this would be a potential limitation on treatment
duration. For this reason, no further experiments were conducted using this
technique.
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Figure 4.1. Effect of treatments to induce hypertension on long-term survival
in AD mouse lines. L-NAME and Ang-II were used to induce hypertension in the
TgSwDI, Tg6799 and TgCRND8 AD mouse lines. After the start of treatment (Day
0), mortality increased in all three mouse lines (A). TgCRND8 mice exhibited the
most extreme drop in survival during treatment, followed by TgSwDI and Tg6799
mice. Frequent seizures were observed in L-NAME and Ang-II-treated mice of each
strain. No increase in mortality was observed in untreated mice. (B) Given this drop
in survival following combined L-NAME and Ang-II treatment, TgSwDI and WT mice
were treated with L-NAME alone. Both groups exhibited an increase in BP from
baseline levels (Day -2) without any associated increase in mortality (not shown)
despite the extended duration of treatment.
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L-NAME-Induced Hypertension
Due to the increased mortality observed in AD mice following Ang-II and L-NAME
administration (Figure 4.1A), L-NAME treatment alone was examined for its effects
on BP (Figure 4.1B). Administration of L-NAME increased BP in both TgSwDI and
WT mice (Figure 4.1B). BP rose gradually after initiation of treatment (Day 0) and
remained elevated after the first 3-4 weeks of treatment. Additionally, treatment of
mice for up to 5 months resulted in no increase in mortality in either genotype (not
shown).

One benefit of this method relative to other treatment types was that the amount of
L-NAME administered could be adjusted easily since L-NAME was delivered in the
drinking water of the mice. Additionally, no surgical incisions were required for LNAME administration. Even if AD mice could tolerate Ang-II treatment alone for an
extended duration, Ang-II was infused through a subcutaneous pump that required a
small incision on the back of each mouse for insertion. Additionally, the infusion
pump used for Ang-II delivery required replacement once contents were expelled
every 2-4 weeks. Thus, the duration of treatment would have been limited by the
cost of the pumps and the number of times animals could be anesthetized and
operated on before suffering extensive surgical trauma. Since long-term L-NAME
administration could best mimic chronic human hypertension, which can last
decades, it was selected as the method for inducing hypertension in TgSwDI mice.
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CHAPTER 5: EFFECTS OF HYPERTENSION ON ALZHEIMER’S
NEUROPATHOLOGY IN TGSWDI MICE
Cognitive Decline
L-NAME was used to chemically induce hypertension in TgSwDI and WT mice
(Figure 5.1). This protocol was designed to mimic the pattern of hypertension that
predisposes humans to LOAD, which occurs in individuals with midlife hypertension
prior to indications of cognitive decline34, 76, 77. Since TgSwDI mice are predisposed
to AD, hypertension was induced at 3-4 months-of-age, which corresponds to early
adulthood in humans, but is before AD-related cognitive decline was observed in this
mouse line (Figure 3.1). Mice were treated for 3 or 6 months and were 6-7 or 9-10
months during testing and analysis, respectively. L-NAME-treated WT and TgSwDI
mice exhibited a significant increase in BP compared to water-treated animals,
which stabilized after the first four weeks of treatment (Figure 5.2A). There were no
differences in levels of CD31 or α-smooth muscle actin between normotensive and
hypertensive groups throughout treatment (not shown), suggesting that hypertension
did not affect the overall number of vessels in brain tissue in these animals. The
Barnes maze was used to compare the cognitive abilities of normotensive and
hypertensive WT and TgSwDI mice. After 3 months of L-NAME treatment, TgSwDI
mice performed significantly worse during the 5-day probe trial compared to watertreated TgSwDI mice and all WT mice (Figure 5.2B), indicating that chronic
hypertension impacted cognition after only 3 months, well before significant cognitive
impairment was evident from the transgene alone. Following 6 months of treatment,
hypertensive TgSwDI mice performed worse during Barnes maze training, taking
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significantly longer to find the escape hole compared to all other groups (Figure
5.2C). Unlike the homozygote cohort (Figure 3.7), there were no differences in
baseline locomotor activity between any of the groups when heterozygotes and
littermate controls were tested (not shown). Interestingly, this cohort of water-treated
TgSwDI mice (9-10 months-of-age) did not have cognitive deficits relative to WT
mice in this test, though chronic hypertension was able to induce significant
cognitive dysfunction.

62

Figure 5.1. L-NAME-induced chronic hypertension experimental setup. IVF was
used to generate a cohort of TgSwDI +/- mice from TgSwDI +/+ and C57Bl6J mice.
The males from this cross and age-matched C57Bl6J males were used to test the
experimental paradigm (pilot group). When they reached 3-4 months-of-age, half of
the mice of each genotype were treated with L-NAME (hypertensive) for 3 or 6
months, at which time they were sacrificed. The rest of the cohort was treated with
water. At 8 weeks of age, the female TgSwDI +/- mice generated from the first cross
were subsequently crossed with C57Bl6J male mice using IVF to generate a new
cohort of TgSwDI +/- and -/- mice (experimental group). Because they were
generated by IVF, all members of the experimental cohort were age-matched and
the controls were littermates. Mice of each genotype were treated with either LNAME or water as described for the pilot group. After 3 or 6 months, behavioral
experiments were conducted and mice were sacrificed for tissue analysis.
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Figure 5.2. Chronic L-NAME treatment induces hypertension in WT and
TgSwDI mice and accelerates AD-related cognitive decline. (A) WT and TgSwDI
mice administered L-NAME in their drinking water exhibited significantly elevated BP
compared to water-treated groups (***p<0.001 for effect of treatment for each
genotype). Mice treated with water maintained constant BP. Treatments started on
day 0, after baseline BP was measured. (B) TgSwDI mice treated with L-NAME for 3
months exhibited cognitive deficits in the Barnes maze relative to untreated TgSwDI
and WT groups. During the probe trial carried out 5 days after training, hypertensive
TgSwDI mice approached the target hole less frequently than normotensive TgSwDI
(*p<0.05) and WT (p<0.05) mice. There was no effect of hypertension on cognitive
function in WT mice. (C) Long-term hypertension, induced by L-NAME treatment for
6 months, affected learning in TgSwDI mice, which exhibited extended latencies to
find the target hole during training compared to normotensive TgSwDI mice
(***p<0.001), an effect not observed after 3 months of L-NAME treatment [not
shown; n=8-12/group (A), 10-12/group (B,C)].
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Vascular Amyloid Deposition
To determine if increased levels of Aβ in the hippocampus were responsible for the
cognitive deficits observed in hypertensive TgSwDI mice, ThioS was used to detect
fibrillar Aβ. Sections were co-stained with an anti-collagen IV antibody, which
recognizes the basement membrane of capillaries. After quantifying the total length
of capillaries stained by collagen IV in the DS of each mouse, the length of vessels
in the same sections that was stained by ThioS was quantified. These values were
used to calculate the percent of DS capillaries with CAA. Aβ in the DS of
normotensive TgSwDI mice was microvascular and parenchymal (Figure 5.3A, D).
However, there were fewer plaques observed in hypertensive TgSwDI mice and
significantly more CAA (Figure 5.3B, E). These results demonstrated that this
microvascular Aβ staining was increased in hypertensive mice compared to
normotensive animals (Figure 5.3C, F), yet there was not an increase in overall Aβ
levels (not shown), suggesting that hypertension increased the likelihood that Aβ
would be deposited microvascularly. The small number of plaques observed in
hypertensive TgSwDI mice (Figure 5.3E) could have been the result of new Aβ
production and/or deposition, since plaque-like deposits of Aβ were observed in
earlier stages of disease before microvascular Aβ deposits were observed (Figure
3.2). Immunoelectron microscopy (IEM) analysis confirmed that the Aβ deposited in
these mice was microvascular. Bundles of electron-dense finger-like clusters
adhered to the basement membrane surrounding microvessels and stained positive
with a pan-amyloid marker (Figure 5.3G).
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Figure 5.3. Hypertensive TgSwDI mice exhibit increased microvascular Aβ
deposition. ThioS (green) and an anti-collagen IV antibody (red) were used to
determine levels of CAA in normotensive (A,D) and hypertensive (B,E) TgSwDI
mice. CAA levels were significantly increased after 3 (B,C) and 6 (E,F) months of LNAME treatment (***p<0.001 or **p<0.01 normotensive TgSwDI vs. normotensive
WT; ***p<0.001 or *p<0.05 normotensive vs. hypertensive TgSwDI; scale bar=50
µm; n=7-8/group). (G) Microvascular Aβ deposition, observed by immunoelectron
microscopy, appeared as dark finger-like projections adhering to the basement
membrane of capillaries in hypertensive TgSwDI brains (L, lumen; E, endothelial
cell; scale bar=500 nm).
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Microgliosis
Since activated astrocytes and microglia are often abundant in tissue with Aβ
deposition78, glial markers were examined in normotensive and hypertensive
TgSwDI and WT brains (Figure 5.4). Though levels of astrocyte markers were
similar in normotensive and hypertensive TgSwDI mice (not shown), the microglial
marker Iba-1 was upregulated in hippocampal subregions of hypertensive TgSwDI
mice compared to those of normotensive mice (Figure 5.4 B,E vs. A,D). Iba-1
expression was significantly higher in water-treated TgSwDI mice compared to
water-treated WT mice and was even higher in L-NAME-treated TgSwDI mice
(Figure 5.4C,F). The pattern of Iba-1 staining in the DG appeared patchy (Figure
5.4B), likely due to the presence of larger parenchymal plaques in this region,
compared to the DS, where the staining appeared vascular (Figure 5.4E). Due to the
vascular appearance of Iba-1 in the DS, electron microscopy (EM) was used to
examine Aβ-laden microvessels and confirm that CAA was often surrounded by
infiltrating microglia (M in Figure 5.4G).
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Figure 5.4. Hypertensive TgSwDI mice display increased vascular
microgliosis. Microgliosis was examined in tissues using an anti-Iba-1 antibody
(green) and vessels were stained with an endothelial cell-specific anti-CD31
antibody (red). Compared to water-treated TgSwDI (A,D) and WT (not shown)
groups, the DG (B) and DS (E) of hypertensive TgSwDI brains exhibited significantly
more Iba-1 staining after 6 months of treatment (C,F; **p<0.01 normotensive
TgSwDI vs. normotensive WT; *p<0.05 or ***p<0.001 normotensive vs. hypertensive
TgSwDI; scale bar=100 µm; n=6-9/group). (G) The infiltration of microglia was
observed by EM of brain capillaries in hypertensive TgSwDI samples. Capillaries
laden with Aβ (*) were surrounded by infiltrating microglial nuclei (M, microglia; L,
lumen; scale bar=2 µm).
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BBB Integrity
Since the BBB is disrupted in AD patients and mouse models79-81, BBB integrity was
examined to determine if hypertension affected this feature of AD pathology. Under
normal conditions, tight junctions, which form the basis of the BBB82, appear
continuous and lay flat, preventing diffusion of blood components into the brain83
(Figure 1.2, 5.5A). However, the tight junctions in samples from hypertensive
TgSwDI mice appeared to be breaking off into the capillary lumen and lifting slightly
from the endothelial cell layer (arrowheads in Figure 5.5B-D), providing an
opportunity for BBB leakage. Given these structural alterations, tissue was examined
for the presence of blood components that could enter the brain if BBB integrity were
compromised. Albumin was elevated in the DS and DG of hypertensive TgSwDI
brains when compared to normotensive TgSwDI brains after only 3 months of
treatment, indicating that BBB integrity was compromised due to hypertension
(Figure 5.5G,H).
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Figure 5.5. Hypertensive TgSwDI mice have increased BBB disruption.
Compared to capillary structure in water-treated mouse vessels (A), capillaries in
brains of hypertensive TgSwDI mice exhibited tight junction alterations (arrowheads
in B-D). Compared to the structure of normal tight junctions (arrow in A), those of
hypertensive TgSwDI mice were often lifting or fragmented (arrowheads in B-D). The
plasma protein albumin, which was present at low levels in the DS of normotensive
TgSwDI brains (E), was significantly enriched in the DS (F-H; *p<0.05) and DG (not
shown) of hypertensive TgSwDI mice after 3 months of L-NAME treatment.
Compared to normotensive WT mice, hypertensive WT mice also exhibited
significant leakage of albumin from the vasculature into the DS after 3 months of LNAME treatment (H, *p<0.05; scale bar in A=1 µm, E=20 µm; n=4-6/group).
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Astrocyte Alterations
Though no changes were observed in levels of astrocyte markers examined in the
experimental cohort (not shown) and despite similarities in microglial markers
between the pilot and experimental cohorts (Figure 5.4, 5.6A,B), initial analysis of
the pilot cohort revealed dramatic changes in astrocytic markers. Levels of glial
fibrillary acidic protein (GFAP) were significantly increased in the hippocampi of
hypertensive TgSwDI mice (Figure 5.6C,D).
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Figure 5.6. Hypertensive TgSwDI mice from the pilot group exhibit increased
microgliosis and astrocyte activation. The elevation in Iba-1 levels in the DS of
hypertensive TgSwDI mice in the experimental group was also seen in hypertensive
TgSwDI mice in the pilot group when examined using an anti-Iba-1 antibody (A,
brown; B, ***p<0.001 normotensive TgSwDI vs. normotensive WT, **p<0.01
normotensive vs. hypertensive TgSwDI). However, the astrocyte marker GFAP,
which was not differentially regulated in hypertensive TgSwDI mice compared to
normotensive animals in the experimental group (not shown), was significantly
increased in hypertensive TgSwDI mice (C) compared to normotensive mice (not
shown) in the pilot group, as well as in hypertensive WT mice compared to
normotensive control mice (D; **p<0.01 normotensive vs. hypertensive WT,
***p<0.001 normotensive TgSwDI vs. normotensive WT, *p<0.05 normotensive vs.
hypertensive TgSwDI). GFAP (red) was observed as dense staining in the DG and
DS (not shown) of hypertensive TgSwDI mice from the pilot group (C, scale bar =
100 µm).
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Additionally, levels of the water channel protein aquaporin-4 (AQP-4) appeared
dramatically misregulated in hypertensive TgSwDI from the pilot group (Figure 5.7).
Overall staining intensity was significantly increased in hypertensive TgSwDI mice
(Figure 5.7D,J) relative to normotensive TgSwDI mice (Figure 5.7C,I), as well as
nomortensive (A,G) and hypertensive WT mice (B,E,H,K). Despite this increase,
localization of the endfoot marker along capillaries was largely absent (Figure
5.7F,L). These changes were subtle in normotensive TgSwDI, but severe in
hypertensive TgSwDI mice. Importantly, hypertensive WT mice exhibited increased
AQP-4 staining intensity as well as vessel coverage (Figure 5.7E,F,K,L), suggesting
that the hypertension-induced alterations that occurred in WTs were misregulated in
TgSwDI mice. Levels of α-syntrophin, an anchoring protein for AQP-4, were also
reduced in the pilot cohort (not shown). Reduction in levels of this protein could
contribute to AQP-4 mislocalization.
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Figure 5.7. Hypertensive TgSwDI mice from the pilot group display
mislocalized protein expression in astrocyte endfeet. The astrocyte endfoot
marker AQP-4 was identified using an anti-AQP-4 antibody (red) in tissue from both
the pilot and experimental cohorts. Despite seeing no differences in AQP-4 staining
in mice from the experimental group (not shown), AQP-4 levels were increased in
both the DG (A-D) and DS (G-J) of hypertensive TgSwDI mice (D, J) compared to
normotensive TgSwDI mice (C, I) after 3 and 6 months of treatment. AQP-4 staining
in normotensive (A,G) and hypertensive (B,H) WT animals showed what appeared
to be vascular staining, consistent with the adherence of endfeet to capillaries. In
hypertensive TgSwDI mice, staining was no longer localized to capillaries (F,L) and
was dramatically upregulated (E,K), a pattern also observed in normotensive
TgSwDI mice, but to a less dramatic extent. Notably, L-NAME treatment increased
both AQP-4 staining intensity and vessel coverage in WTs, suggesting that the effect
of hypertension on AQP-4 levels is misregulated in TgSwDI mice (*p<0.05, **p<0.01,
***p<0.001; scale bar = 50 µm).
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Pericyte Loss
Pericyte loss occurs in severely affected AD patients84 and in older TgSwDI mice28,
so levels of PDGFRβ were quantified to determine if the expression of this pericyte
marker was altered in hypertensive groups. After 6 months of L-NAME treatment,
hypertensive TgSwDI mice exhibited a significant decrease in PDGFRβ staining in
both the DG and DS (Figure 5.8 A,D vs. B,E). Taken together, these results suggest
that pericyte loss can occur at a much earlier age when there is concomitant
hypertension.
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Figure 5.8. Hypertensive TgSwDI mice exhibit early pericyte loss. Anti-PDGFRβ
antibody was used to examine pericyte coverage of vessels in normotensive (A,D)
and hypertensive (B,E) TgSwDI mice. (C,F) PDGFRβ levels were significantly
reduced in hypertensive TgSwDI mice in the DG and DS compared to control groups
after 6 months of treatment (*p<0.05, **p<0.01; scale bar=50 µm; n=5-9/group).
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Neuronal Loss
Neurodegeneration is a hallmark feature of AD, but many mouse models of this
disease do not exhibit this pathology83. Under normal conditions, the TgSwDI mouse
model also does not show signs of neuronal loss85. However, due to the accelerated
timecourse of other pathologies in L-NAME-treated TgSwDI mice, the hippocampus
was examined and exhibited significantly reduced neuronal staining in the DS
(Figure 5.9). This degeneration occurred after short-term L-NAME treatment (3
months) and at only 6-7 months-of-age, when no neuronal loss was evident in
normotensive TgSwDI mice (Figure 5.9 A-C). Normotensive TgSwDI mice at 9-10
months-of-age began to exhibit signs of neuronal loss (Figure 5.9D), making
hypertension-induced cell death at this age less dramatic (Figure 5.9F).
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Figure 5.9. Hypertensive TgSwDI mice exhibit early neuronal loss. Anti-NeuN
antibody was used to identify neurons in the DS of normotensive (A,D) and
hypertensive (B,E) TgSwDI mice. (C) Reduced NeuN intensity was observed in
hypertensive TgSwDI mice after 3 months of L-NAME treatment (*p<0.05, n=39/group). (F) Since NeuN intensity was slightly decreased in normotensive TgSwDI
animals after 6 months of treatment due to advanced age (9-10 months-of-age),
there was no longer a significant difference between groups. Although NeuN
intensity appeared reduced in the DS of hypertensive WT mice compared to
normotensive WT mice after 3 and 6 months of treatment, neither change was
significant (C,F; *p<0.05; scale bar=50 µm; n=5-9/group).
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Although the pericyte loss observed in hypertensive TgSwDI mice (Figure 5.8) has
been reported in 18 month-old TgSwDI homozygote mice without hypertension28,
neuronal loss has never been reported in this mouse model at any age. This is an
important finding, since neuronal loss is a widely accepted hallmark of AD, yet does
not occur in many commonly used AD models86.
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CHAPTER 6: EFFECTS OF HYPERTENSION ON AUTOPHAGY IN TGSWDI MICE
Increased Autophagy in Hypertensive TgSwDI Mice at the NVU
Autophagy was first identified using EM techniques87 and EM is still used to identify
autophagic compartments morphologically	
  46. EM has superior resolution compared
to light microscopy and many antibodies used to identify autophagic compartments
by immunofluorescence or light microscopy are unsuccessful. By EM, lysosomes
appear as uniformly electron-dense intracellular spheres87. Endosomes and MVBs,
which have been reported to carry Aβ into cells for degradation in AD88, appear as
round bodies containing smaller spheres of various electron densities89.

Early ultrastructural observations of hypertensive TgSwDI brain tissue revealed
abundant autophagic activity. Lysosomes and MVBs were often present near sites of
CAA in hypertensive TgSwDI brain tissue processed for EM (Figure 6.1) and have
been observed in all cellular components of the NVU, including microglia, pericytes,
astrocytic endfeet and endothelial cells, within a narrow block of tissue at one time
(not shown). This is unusual, since it is rare to see lysosomal activity in healthy brain
tissue due to the rapid rate of autophagic flux42. Both microglia and astrocytes are
known to take up and degrade Aβ deposited in AD8, 90. However, the participation of
pericytes, endothelial cells and the endfeet of astrocytes in clearance of CAA has
not been reported.
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Figure 6.1. Lysosomes are present in multiple NVU cell types in hypertensive
TgSwDI mice. (A-D) EM images showed the presence of lysosomes, which
appeared as electron-dense spheres, in multiple cell types in hypertensive TgSwDI
brain tissue. (A) Microglia nuclei (*) were present at the basement membrane of a
capillary, likely due to the presence of Aβ nearby (not shown). The dark spheres
within the microglia shared morphological characteristics with lysosomes
(arrowhead), while the nearby round bodies containing spheres of different electron
densities were morphologically similar to MVBs. Lysosomes and/or MVBs were also
abundant in pericytes (B), astrocyte endfeet (C) and endothelial cells (D) in
hypertensive TgSwDI mice (L, lumen; scale bar = 2 µm in A, 1 µm in B,C,D).
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Lysosomal Protein Expression is Increased in Hypertensive TgSwDI Mice

Given the increased abundance of lysosomes observed in NVU cell types in
hypertensive TgSwDI brains, levels of autophagic markers were examined in brain
sections from these animals (Figure 6.2). LAMP-1 was used as a marker as
previously described for the characterization of neuropathology in TgSwDI
homozygous mice (Figure 3.5). Levels of LAMP-1 were significantly increased in
hypertensive TgSwDI mice (Figure 6.2A,B). The staining pattern of LAMP-1 in the
DS resembled that of microglia in the same mice (Figure 5.4E), consistent with the
observation of lysosomes in microglia (Figure 6.1) as well as in other NVU cell types.
Cathepsin D (CATD), a lysosomal aspartyl protease involved in degradation of
proteins within lysosomes	
  91, was also increased in hypertensive TgSwDI mice
(Figure 6.2 C,D) and showed a similar staining pattern to that of Iba-1 and LAMP-1
(Figure 5.4E, 6.2A). Microglial co-staining is required to confirm cell type-specific
expression of these markers.
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Figure 6.2. Levels of lysosomal markers are increased in hypertensive
TgSwDI mice. Given the abundance of lysosomes observed by EM at the NVU in
hypertensive TgSwDI mouse brains, tissue sections from hypertensive TgSwDI mice
were examined for the presence of lysosomal markers. Levels of LAMP-1, a protein
found on endosomal and lysosomal membranes, were increased in the DS of both
normotensive (not shown) and hypertensive TgSwDI (A) groups relative to WT
groups (B, ***p<0.001). Moreover, levels of LAMP-1 were significantly increased in
hypertensive TgSwDI mice relative to normotensive TgSwDI mice (B, **p<0.01).
Since LAMP-1 is not specific for lysosomes, levels of the lysosomal protease CATD
were examined using an anti-CATD antibody. Again, both normotensive (not shown)
and hypertensive TgSwDI (C) groups exhibited a significant increase in CATD levels
relative to WT mice (D, **p<0.01). Elevated levels of CATD were also observed in
hypertensive TgSwDI mice relative to normotensive TgSwDI mice (D, ***p<0.001),
similar to what was observed with LAMP-1 staining (scale bar = 50 µm).
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Effect of Hypertension on Astrocyte Endfoot Morphology

By EM, astrocyte endfeet appeared less electron-dense than surrounding cells
(Figure 1.2). In normotensive WT mouse brains, lysosomes as well as vacuolar
structures within astrocyte endfeet were occasionally observed (not shown).
However, such vacuoles were abundant in astrocyte endfeet in both hypertensive
WT (Figure 6.3A) and hypertensive TgSwDI mice (Figure 6.3B).

These vacuoles were morphologically similar to structures observed in primary
cortical neuron cultures from rat pups after induction of autophagy by rapamycin
treatment42. These structures are also morphologically similar to known autophagic
structures: MVBs, AVs and multilamellar bodies (MLBs) (Figure 6.4). Thus, it is
possible that the vacuolar structures observed in the endfeet of hypertensive
TgSwDI and WT mouse brains were produced during autophagic flux. However,
since the identity of these structures has not yet been confirmed by IEM analysis or
by examination after induction or suppression of autophagy, they will be referred to
as autophagic compartments (ACs) herein. In hypertensive TgSwDI and WT brain
tissue, ACs are so abundant that they appear to cause dramatic swelling of the
astrocyte endfeet (Figure 6.3).
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Figure 6.3. Hypertension causes buildup of ACs in swollen astrocyte endfeet.
The buildup of ACs is most noticeable in the astrocyte endfeet of hypertensive WT
(A) and TgSwDI (B) mouse brains. Astrocyte endfeet are typically more electrondense than surrounding tissue (Figure 1.2). In hypertensive TgSwDI and WT mice,
the accumulation of ACs resulted in a dramatic enlargement of these astrocytic
processes. In (A), two MLBs (arrow) are observed amongst the ACs while in (B), a
lysosome (arrowhead) can be observed (L, lumen; scale bar = 2 µm).
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Figure 6.4. ACs in hypertensive mice share morphological features with
autophagic structures. ACs observed using EM in hypertensive WT (A) and
TgSwDI (B,C) mice resemble different autophagic structures. The round
compartments and darker components contained within the membrane of the AC
shown in A resemble features of an MVB. The structure in B is morphologically
similar to an AV, which has membranes surrounding less electron-dense
components. An AC that shared characteristics of an MLB can be observed in C.
Due to their morphological similarities to a variety of different autophagic structures,
ACs may refer to multiple entities, rather than one discrete type of autophagic body
(scale bars = 500 nm).
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Clearance of ACs Through the BBB
Further EM analysis revealed that ACs were often localized within tight junctions of
endothelial cells in hypertensive TgSwDI and WT mice (Figure 6.5). The localization
of ACs to tight junction structures may have altered the permeability of the BBB and
contributed to the BBB leakage observed in hypertensive TgSwDI and WT mice
(Figure 5.5).
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Figure 6.5. ACs are cleared through the BBB in hypertensive mice. ACs are
often abundant within tight junction structures in hypertensive WT (A,B) and TgSwDI
(C,D) mice, but never in normotensive WT or TgSwDI mice (not shown). Moderate
(A,C) to severe (B,D) disruption of the tight junctions can be observed in the brains
of hypertensive mice of both genotypes (scale bar = 500 nm). The disruption of tight
junctions in hypertensive mice due to the presence of ACs may contribute to the
reduced BBB integrity observed in these animals.
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The frequent presence of ACs within the lumen of capillaries in hypertensive mice
(Figure 6.6) suggests active clearance of these structures from the brain to the
blood. Clearance of ACs could have occurred through endothelial tight junctions
(Figure 6.5) or through exocytosis by endothelial cells (Figure 6.7). Clearance of
autophagic structures into the blood has not been reported previously, so should be
considered with caution. However, potentially similar mechanisms, such as receptormediated transcytosis, have been reported92.
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Figure 6.6. Hypertension causes buildup of ACs in the capillary lumen.
Lumenal ACs were observed in brain capillaries of hypertensive TgSwDI (A,B) and
WT (C) mice. ACs were observed in the lumen of capillaries at low (A), moderate (B)
and high (C) abundance in hypertensive mice of both genotypes. The presence of
ACs in the capillary lumen suggests that ACs were being cleared from the brain into
the circulation (scale bars = 500 nm).
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It is likely that the ACs observed in the lumen of capillaries by EM (Figure 6.6) were
in the process of being exocytosed by endothelial cells, since completely detached
structures would have been carried away by capillary flow or perfusion. Threedimension electron microscopy (3D-EM) revealed that ACs that appeared to be
detached in the lumen were actually attached to endothelial cells at nearby points
not captured in the EM image (Figure 6.7).
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Figure 6.7. ACs are exocytosed from endothelial cells in hypertensive mice.
Sequential EM images processed using 3View are presented in order of image
collection from left-to-right and top-to-bottom. Early during image capture, the AC
(red box) observed in the capillary lumen of a hypertensive TgSwDI mouse,
appeared completely lumenal. Images captured at different points along the Z-axis
(presented here at 100-nm intervals) show that the AC was attached to the nearby
endothelial cell. The endothelial cell appeared to be in the process of exocytosing
the AC into the capillary lumen (scale bar = 1 µm).
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Though ACs were occasionally observed in astrocyte endfeet in normotensive WT
mice, they were very rarely observed within the lumen of capillaries in normotensive
TgSwDI or normotensive WT mice (not shown). Notably, they were never observed
within tight junction structures in normotensive animals. For this reason, the ACs that
appeared to disrupt the BBB seem to be a product of hypertension.
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CHAPTER 7: DISCUSSION AND CONCLUSIONS
Pathological Timecourse in TgSwDI Mice
The hippocampus coordinates memory consolidation and spatial navigation and is
one of the first regions in the brain to suffer damage in AD93. The DG receives all
hippocampal inputs and passes them through the hippocampus proper (CA1-4) to
the subiculum, which projects out of the hippocampus to the entorhinal cortex94.
Thus, proper function of the DG, which receives all hippocampal inputs, and the
subiculum, which sends hippocampal projections, are essential to memory
consolidation and spatial navigation. Additionally, rat studies suggest that the
subiculum is involved in the spread of Aβ, as lesions in this region inhibit plaque
formation in other brain regions95. The earliest pathological changes observed in the
TgSwDI mouse model occurred in the subiculum (Figure 3.2-3.5). It is unclear why
this occurs, since expression of the APP transgene is not localized to particular brain
regions in the TgSwDI mouse line. The cognitive deficits observed in TgSwDI mice
as well as the pathological progression observed throughout the brain over time may
be due in large part to the presence of early pathology in the subiculum.

Given the abundance of Aβ plaques in brains of humans with severe AD, it is
unclear whether Aβ deposits are a contributor to dysfunction in the disease or
merely an indication of pathological severity. Interestingly, at 2 months-of-age,
TgSwDI mice exhibited dramatic microglia activation in the DS (Figure 3.3D) relative
to the amyloid deposited at this age, which was undetectable (Figure 3.2A). Since
the transgenic mutations in TgSwDI mice result in overproduction of Aβ, it is
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reasonable to assume that Aβ production is the cause of the early microglial
activation, since no activation was observed in WT mice at any age (Figure 3.3).
Importantly, though no fibrillar Aβ deposits were detected in TgSwDI mice at 2
months-of-age by ThioS staining, soluble forms of Aβ may still have been present
and may have resulted in the observed activation of microglia. LAMP-1 staining was
also increased in TgSwDI mice at around 3 months-of-age, again prior to
widespread plaque or CAA pathology. The timecourse of these changes suggests
that microglial activity at 2 months-of-age was able to keep Aβ deposition low, but
was overwhelmed at around 3 months-of-age when Aβ deposition was first observed
in these mice (Figure 3.2B). At this age, observable increases in autophagy were
also noted (Figure 3.5B). Alternatively, early soluble forms of Aβ could have
fibrillized after reaching a certain threshold. It is unclear whether changes in
expression of autophagy markers represent dysfunctional autophagy or simply
upregulated autophagy serving to control the increasing Aβ load in the brain. It is
also unclear whether fibrillar and oligomeric forms of Aβ had different effects on the
microglia activation or autophagic processes observed96, 97. It is possible that early
mechanisms acting to clear plaques observed at 3 months-of-age resulted in
microvascular deposition of Aβ by 6 months-of-age, as well as a reduction in plaque
size and number. It is also possible that early plaques were easily cleared, while
amyloid deposited as CAA occurred later during the pathological timecourse, but
persisted.
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Breakdown of the BBB was observed as early as 3 months-of-age in TgSwDI
homozygotes. Since Aβ deposition was not severe and was also not vascular at 3
months-of-age (Figure 3.2B), the early increases in microgliosis and autophagy may
be more directly linked to loss of BBB integrity than Aβ abundance or CAA. If
opening of the BBB were in fact a mechanism for removal of Aβ from the brain, as
proposed in Chapter 6 (Figure 6.5, 6.7), the timescale of increased BBB permeability
is consistent with the timescale of other clearance mechanisms relative to Aβ load.
However, the basis for such a hypothesis is not well established and requires
confirmation.

Accelerated Neuropathology in Hypertensive TgSwDI Mice
Under normal conditions, hypertension induces pathological changes within the
cerebral vasculature, resulting in impaired autoregulation, microbleeds, and lacunar
infarcts, as well global downstream changes, such as WMLs and atrophy31, 98-103. In
fact, these changes within the cerebral vasculature of hypertensive individuals also
occur in AD patients in the absence of hypertension104-106. Additionally, midlife
hypertension is a significant risk factor for the development of AD later in life16.
Hypertension may initiate vascular damage prior to the onset of AD, allowing
symptoms to be more pronounced and progress more quickly after onset.
Additionally, compromised vessels may be more vulnerable to the deleterious effects
of Aβ. For example, since hypertension results in reduced BBB integrity (Figure 5.5),
blood components may enter the brain before large-scale accumulation of Aβ
occurs. These blood components may serve as a seed for Aβ deposition and
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increase vascular inflammation (Figure 5.4), resulting in cellular damage and the
release of toxic molecules107.

The location, but not abundance, of Aβ deposits was altered in hypertensive TgSwDI
mice, which also exhibited dramatic cognitive decline. These findings suggest that
microvascular Aβ contributed more to cognitive decline than parenchymal plaques.
CAA deposits were found to adhere to capillary basement membranes (Figure
5.3G), which normally bind NVU cells together. For this reason, Aβ deposited as
CAA may act as a physical barrier to cell signaling at the NVU. Moreover, CAA could
obstruct astrocyte endfoot binding and contribute to pericyte loss (Figure 5.8). Both
astrocytes and pericytes are involved in the recruitment of blood flow during
neuronal activity and damage to or interference with signaling of these cell types in
hypertensive TgSwDI mice may impair neurovascular coupling.

Aβ is thought to be deposited as CAA due to failed clearance across the BBB and
along perivascular spaces108. Since L-NAME treatment resulted in increased CAA in
TgSwDI mice without an overall increase in Aβ levels, hypertension may have a
detrimental effect on these Aβ clearance pathways. L-NAME inhibits eNOS and
thereby prevents the production of the vasodilator NO. It could be that NO-mediated
vasodilation is required for effective clearance of Aβ across the BBB or along
perivascular drainage pathways. If L-NAME disrupted this process, Aβ would be
preferentially deposited along capillaries, as observed in hypertensive TgSwDI mice.
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The neuronal loss in hypertensive TgSwDI mice (Figure 5.9) could have resulted
from the proposed reductions in blood flow as well as impaired function of NVU
support cells that either degenerate (pericytes; Figure 5.8) or are chronically
activated (microglia; Figure 5.4). Since brain atrophy is associated with hypertension
in humans 31 and hypertensive WT mice exhibited a trend towards reduced neuron
number, it is possible that the vascular changes that occur during hypertension in
WT mice, such as BBB leakage (Figure 5.5), affect neuronal health. However, the
changes specific to TgSwDI mice with hypertension, such as dramatically increased
microgliosis (Figure 5.4) and severe CAA (Figure 5.3) likely contributed in some
way. In addition to the cytotoxic effects of Aβ itself109-111, activated microglia are
known to produce cytotoxic molecules107, which may damage neurons. Therefore,
the increased microvascular Aβ deposition and microgliosis in hypertensive TgSwDI
mice, but not in hypertensive WT mice, may have contributed to the neuronal loss
observed in this group.

Though models of comorbid hypertension and AD are limited, the results presented
here are consistent with what has been observed in other models. Ang-II infusion in
APPPS1 mice results in a more rapid onset of AD pathology112. It is possible that
long-term hypertension facilitated by the use of L-NAME exacerbated previously
observed pathologies, such as cognitive decline (Figure 5.2) and early and dramatic
Aβ deposition (Figure 5.3), and revealed new neuropathologies not previously
observed, such as microglia activation (Figure 5.4), BBB leakage (Figure 5.5), and
pericytic and neuronal loss (Figure 5.8, 5.9).
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Studies linking hypertension with AD define midlife as the time between the ages of
40 and 64 years. Midlife hypertension is associated with an increased risk of
developing AD, but hypertension later in life (≥65 years-of-age) does not have this
association. Given that heterozygous TgSwDI mice developed AD symptoms around
6 months-of-age (Aβ deposition, microgliosis; Figures 5.3, 5.4) and cognitive decline
around 10-12 months (not shown), hypertension was induced at a time point
corresponding to early adulthood developmentally, to maximize the duration of
hypertension before the onset of AD symptoms. Importantly, studies linking
hypertension with AD examine BP prior to onset of AD symptoms. Though midlife
hypertension is a significant risk factor for AD and treatment alleviates this risk34, 36,
dramatic reduction in BP often occurs at later stages of AD, after which point
antihypertensive use is deleterious to cognitive function33, 34. Hypertension may
compromise vascular integrity during midlife and lead to cellular, basement
membrane and/or BBB damage. However, after the onset of AD symptoms, low BP
may aggravate brain hypoperfusion already present in AD due to other types of
vascular damage. Additionally, since patients exhibit low BP during moderate and
severe AD stages, rather than during mild cognitive impairment, and since the
association between low BP and AD becomes stronger in more severe cases of AD,
it has been proposed that AD somehow causes the low BP observed in patients35.
This may be due to loss of or damage to cell types that control blood flow or it could
be a result of other changes that often occur over the course of the disease, such as
weight loss and reduced activity.
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Although others have shown pericyte loss in TgSwDI mice at 18 months-of-age28, LNAME-induced chronic hypertension caused pericyte loss significantly earlier (9-10
months-of-age; Figure 5.8). Furthermore, neuronal loss has never been reported in
this transgenic model, yet hypertensive TgSwDI mice demonstrated significant
neurodegeneration in a subregion of the hippocampus (Figure 5.9). Moreover, not
only did hypertension result in quantifiable neuronal loss, but it did so quite early (6-7
months-of-age) relative to the few other mouse lines that exhibit this feature of
AD113. At 6-7 months-of-age, the first indications of AD (Aβ deposition,
neuroinflammation, cognitive decline) are often just becoming apparent in other AD
mouse models113-115. These findings are notable, since neuronal loss is widely
accepted as a hallmark of AD, yet does not occur in many commonly used AD
models86. If hypertension indeed accelerates AD pathogenesis, then a reasonable
hypothesis is that neuronal loss is a downstream effect of the abundant
microvascular amyloid pathology observed in TgSwDI mice. Neuronal loss is often
not reported in AD mice possibly due to their short lifespans relative to the time
required for AD to result in neuronal loss in humans. Pairing hypertension with
genetic predisposition to AD may represent a more complete model of AD than
traditional AD mouse models.

The Effects of Hypertension on Autophagy in TgSwDI and WT Mice
Abnormalities of the lysosomal system have been identified in the AD brain, though
these findings have only been described in neurons116. Given that CAA is increased
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in hypertensive TgSwDI mice (Figure 5.3) without increased overall levels of Aβ or
an altered ratio of Aβ40 to 42 compared to normotensive TgSwDI mice (not shown)
and that lysosomal markers LAMP-1 and CATD are also increased in hypertensive
TgSwDI mice, it is possible that Aβ deposited microvascularly differentially affects
autophagic processes relative to Aβ deposited as plaques in the brain. This process
could be due to the cell types located near CAA and the ability of these cell types to
take up and degrade Aβ (Figure 1.2). Although CAA seems to increase autophagic
flux in NVU cell types, the most dramatic changes in autophagic processing appear
to be brought about by hypertension.

Typically when identification of autophagic structures is based on morphology alone,
only vesicles containing cytoplasmic material, in most cases ribosomes or
mitochondria, can be called autophagic in mammalian cells117. Given the lack of
electron-dense material inside ACs, the supposition that they may be remnants of an
autophagic process is purely speculative.

Normal AV induction, but impaired clearance would theoretically result in an
abundance of membrane-bound compartments with little electron-dense material
inside116. The ACs observed in hypertensive brains are most similar in appearance
to AVs, a term which has been used to refer to autophagosomes, amphisomes and
autolysosomes. Thus, AV is a general term for autophagy-related vesicular
structures at an intermediate stage in autophagic flux 116. AVs are less electrondense than MVBs and have fewer surrounding membranes than MLBs (Figure 6.4).
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However, since structures resembling AVs, MVBs and MLBs have been observed in
the brains of hypertensive mice, it is possible that “AC”, as it is used here, refers to a
group of structures at different points in autophagic processing.

In general, the ratio of early to late autophagic compartments is indicative of the
cause of accumulation117. ACs in hypertensive animals appear to be at a late stage
of clearance due to their lack of electron-dense components, since even late
autophagic compartments typically still contain electron-dense material117.
Accumulation of late autophagic compartments, may suggest a defect in ultimate
degradation of these structures.

Autophagy is induced in heart tissue during hypertensive heart disease118 as well as
in neurons in the brains in hypertensive animals119. Hypertension is also known to
increase levels of Aβ in WT mice due to RAGE-mediated Aβ-influx through
endothelial cells37. Since ACs were rarely observed in normotensive TgSwDI mice,
despite their high Aβ load relative to hypertensive WT mice, it is possible that the
mechanism by which Aβ enters the brain is involved in production of ACs.
Importantly, APP is present in membranes of organelles involved in autophagy47 and
Aβ production may be elevated during the increased autophagic flux that occurs
during hypertension. Hypertension could also alter autophagic processes at the NVU
by causing damage to the cell types responsible for Aβ clearance. If cells are
prevented from properly degrading Aβ, this could result in the observed buildup of
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ACs in hypertensive TgSwDI and WT brains (Figure 6.3, 6.5, 6.6), as well as the
increased CAA in hypertensive TgSwDI mice (Figure 5.3).

Since ACs were observed in the lumen of capillaries in normotensive WT mice,
albeit rarely, clearance of ACs through endothelial cell exocytosis may be a transient
mechanism for the transfer of brain components to the blood. This process may play
a role in cellular waste removal from the brain, supplementing clearance along
perivascular drainage pathways108. This process could turn over rapidly in
normotensive WT mice, but could be altered in hypertensive animals leading to
buildup of ACs near endothelial cells.

Whether the proposed opening of the BBB for clearance of ACs would result in
improved removal of cellular waste components from the brain or a dramatic
infiltration of blood components into the brain and subsequent neuroinflammation is
unclear. Deleterious changes involving increased BBB permeability, such as
microhemorrhage and increased risk of stroke, have been observed in AD12, 13.
However, some recent studies have shown that focused ultrasound (FUS) is
effective in clearing Aβ from the brain and restoring cognitive abilities in rodent
models of AD120, due to activation of glia and transient and focal opening of the BBB
to endogenous antibodies. Importantly, neither the increased BBB permeability in
TgSwDI mice due to hypertension (Figure 5.5) nor the increase in microglial
activation (Figure 5.4) appears to have a positive effect on cognitive function (Figure
5.2) or Aβ-load (Figure 5.3). Perhaps the presence of increased levels of Aβ within
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the microvasculature impacts the infiltration of useful endogenous antibodies into the
brain in TgSwDI mice. Importantly, FUS appeared to have an effect on the activation
state of microglia, as they increase in size, though not in number, after FUS. The
increased Iba-1 staining in hypertensive TgSwDI mice does not necessarily reflect a
microglial state of increased Aβ clearance. Additionally, FUS localizes BBB
permeability to specific areas rather than increasing general BBB permeability,
which could have different effects on Aβ clearance.

In tissue from hypertensive TgSwDI mice with CAA, endfeet appeared to be
enlarged due to abundance of ACs that collected there (Figure 6.3). Swollen
astrocyte endfeet have been observed in a variety of conditions from schizophrenia
to ischemia, as well as in CAA21, 22, 121, 122. However, since ACs are poorly defined
currently, the similarity of swollen astrocyte endfeet in hypertensive TgSwDI mice
compared to swollen endfeet observed in other conditions is unclear. Since
astrocyte endfeet perform quite a large number of neuronal support functions at the
NVU123-125, disruption of their morphology and function could have dramatic effects
on neuronal health and function. Given the close physical relationship between
astrocyte endfeet and CAA, as well as the increased presence of ACs within
endfeet, it is very surprising that the experimental cohort did not show disruption in
astrocytic markers (not shown). Since ACs are occasionally observed in astrocyte
endfeet in normotensive WT tissue, though never within tight junction structures (not
shown), it is unclear whether they are part of a normal process that occurs
transiently in WT brains or whether they are indicative of pathology. It is possible
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that the endfeet are a common site for autophagic processes given the welldescribed role of astrocytes in degradation and protein clearance9. However, this
process may be disrupted due to hypertension and thus ACs appear much more
frequently near hypertensive capillaries in the brain.

Future Directions
Most of the changes observed in the hypertensive TgSwDI mice from the
experimental cohort were also observed in the pilot cohort (not shown). However,
differences in astrocyte markers in the hypertensive TgSwDI group in the pilot cohort
(Figures 5.6, 5.7) were not recapitulated in the experimental cohort. One difference
between these two cohorts that could account for this difference is that the pilot
cohort contained only male mice. This was due to the fact that the females were
undergoing a second round of IVF in order to generate mice for the experimental
cohort. The presence of estrogen in the brains of female mice may be slightly
neuroprotective126. If repeated analysis reveals that important astrocyte markers are
normal in hypertensive TgSwDI brains from the experimental cohort, repeating the
experiment using only male mice may be useful in order to investigate additional
features of astrocyte pathology.

It would be interesting to examine levels of tight junction proteins in hypertensive
and normotensive brains of each genotype to determine if markers of tight junctions
are altered. Reduced expression of tight junction markers may contribute to the
fragmentation of tight junctions observed by EM in hypertensive TgSwDI mice
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(Figure 5.5) and the disrupted tight junction structures in hypertensive TgSwDI and
WT mice due to the presence of ACs and the BBB leakage observed in these
animals (Figure 5.5).

Previous attempts to confirm that the ACs were indeed autophagic by IEM were
unsuccessful, because techniques required for ultrastructural preservation can
interfere with antigenicity. This work is ongoing with different antibodies that might
display stronger binding to tissue fixed for EM. It would also be useful to know if the
ACs contain soluble Aβ, such as the more toxic oligomeric forms of the protein127. I
would expect this to be the case if transcytosis of ACs were a mechanism for
removal of Aβ from the brain, rather than simply evidence of dysfunctional lysosomal
clearance mechanisms. The fact that levels of Aβ oligomers in plasma negatively
correlate with AD severity in patients, suggests that clearance through the blood
may reflect a mechanism for preserving cognitive ability and when it is disrupted,
cognitive function suffers128.

Though EM is very useful for the qualitative study of cellular phenomena,
quantification of findings by EM can be more challenging than by traditional light or
fluorescence microscopy. Measurement of the ratio of early to late autophagic
compartments by Western blotting may provide insight into the disruption that occurs
in hypertensive mice. Unfortunately, less is known about molecular markers involved
in clearance of autophagic structures than formation and maturation42. Comparison
of hypertensive and normotensive WT mice may also provide information regarding
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the nature of ACs, since autophagic flux appears to occur normally in normotensive
WT mice. To what extent ACs build up in astrocytes and tight junctions in
hypertensive WT compared to hypertensive TgSwDI mice also remains to be
determined. Finally, examination of human tissue with and without hypertension and
with and without comorbid AD will be important to confirm that the findings described
are relevant to humans with these conditions and not an artifact of L-NAME
treatment itself.

APOE is involved in cellular uptake of Aβ as well as trafficking of Aβ to lysosomes in
an isoform-dependent manner129. Interestingly, there is a stronger correlation for
protective effect of antihypertensive drug use among APOE4 carriers130, 131.
Antihypertensive drug use appears to abolish the risk of LOAD conferred by the
APOE4 allele. This correlation could be explained by a common effect of APOE4
and hypertension on autophagy. If both risk factors disrupted autophagic processes,
then their coincidence would exacerbate the effect of one or the other alone.
Examining brain tissue from APOE4 individuals with and without hypertension could
shed light on the interaction between these two risk factors.

Understanding the molecular pathways responsible for buildup of ACs as well as the
proposed exocytosis through endothelial cells could potentially prove therapeutically
useful. If AC exocytosis through endothelial cells were a mechanism for removal of
cellular waste, enhancing this process may prove beneficial, especially in the case of
hypertension, where the process appears to occur inefficiently. If this process
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instead results in loss of BBB integrity and leakage of blood components into the
brain, inhibiting it might prove more therapeutically beneficial.
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